[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1058
1. Ouaïssi M, Panis Y, Sielezneff I, Alves A, Pirrò N, Robitail S, Heyries L, Valleur P, Sastre B: Long-term outcome after ampullectomy for ampullary lesions associated with familial adenomatous polyposis. Dis Colon Rectum; 2005 Dec;48(12):2192-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome after ampullectomy for ampullary lesions associated with familial adenomatous polyposis.
  • PURPOSE: Up to 90 percent of patients with familial adenomatous polyposis develop adenomas in the upper gastrointestinal tract.
  • Besides pancreaticoduodenectomy, which remains indicated in duodenal and ampullary cancer, less aggressive surgical procedure (such as ampullectomy) must be evaluated in selected patients with familial adenomatous polyposis patients presenting low-risk benign duodenal adenomas.
  • METHODS: From 1995 to 2000, we performed a retrospective, observational study, which included eight patients (5 females) with familial adenomatous polyposis underwent ampullectomy (with frozen sections) for presumed benign polyposis lesions.
  • During endoscopic follow-up, although all the patients underwent endoscopic resection of duodenal polyps, none presented recurrence at the ampullectomy site.
  • CONCLUSIONS: Ampullectomy could be safely proposed in selected familial adenomatous polyposis patients.
  • [MeSH-major] Adenomatous Polyposis Coli / surgery. Ampulla of Vater / surgery. Digestive System Surgical Procedures / methods
  • [MeSH-minor] Adenoma / prevention & control. Adult. Aged. Anal Canal / surgery. Anastomosis, Surgical. Colonic Neoplasms / prevention & control. Female. Follow-Up Studies. Humans. Ileum / surgery. Male. Middle Aged. Morbidity. Pancreatic Neoplasms / prevention & control. Pancreaticoduodenectomy. Retrospective Studies. Risk Factors


2. Slice LW, Chiu T, Rozengurt E: Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways. J Biol Chem; 2005 Jan 14;280(2):1582-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase-2 (COX-2) is aberrantly expressed in premalignant adenomatous polyps and colorectal carcinomas and is associated with increased epithelial cell proliferation, decreased apoptosis, and increased cell invasiveness.
  • Inhibition of ERK activation by U0126 or PD98059 significantly decreased EGF-dependent COX-2 expression, but did not affect Ang II-dependent COX-2 expression.
  • Conversely, inhibition of p38MAPK by SB202190 or PD169316 inhibited COX-2 expression by Ang II, but did not block COX-2 induction by EGF.
  • EGF did not induce Ca2+ mobilization, and 2-aminobiphenyl borate did not inhibit EGF-dependent COX-2 expression.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15525649.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK017294; United States / NIDDK NIH HHS / DK / DK055003; United States / NIDDK NIH HHS / DK / DK056930; United States / NIDDK NIH HHS / DK / DK061485; United States / NIDDK NIH HHS / DK / DK063983
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptor, Angiotensin, Type 1; 11128-99-7 / Angiotensin II; 62229-50-9 / Epidermal Growth Factor; DCR9Z582X0 / Epoprostenol; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.6.5.2 / Monomeric GTP-Binding Proteins; EC 3.6.5.2 / cdc42 GTP-Binding Protein
  •  go-up   go-down


3. Rao CV, Yang YM, Swamy MV, Liu T, Fang Y, Mahmood R, Jhanwar-Uniyal M, Dai W: Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad Sci U S A; 2005 Mar 22;102(12):4365-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenomatous polyposis coli (Apc) gene also plays an important role in regulating genomic stability, as mutations of Apc cause aneuploidy.
  • Here we show that whereas Apc(Min)(/+) mice developed many adenomatous polyps, mostly in the small intestine, by 3 mo of age; BubR1(+/-)Apc(Min)(/+) compound mutant mice developed 10 times more colonic tumors than Apc(Min)(/+) mice.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jun 9;101(6):635-45 [10892650.001]
  • [Cites] Cell. 1997 May 30;89(5):727-35 [9182760.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):355-9 [11201745.001]
  • [Cites] Curr Biol. 2001 Jan 9;11(1):44-9 [11166179.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):818-22 [11221861.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Cell. 2001 Jun 1;105(5):563-6 [11389825.001]
  • [Cites] Mol Cell. 2002 Sep;10(3):439-40 [12408813.001]
  • [Cites] J Cell Biol. 2003 Feb 3;160(3):341-53 [12551952.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] J Cell Biol. 2003 Dec 8;163(5):949-61 [14662741.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Jan;5(1):45-54 [14708009.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):440-5 [14744753.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1278-85 [14576056.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):11-6 [15108799.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2978-91 [15075372.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):744-9 [15208629.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1159-61 [15475955.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1144-5 [15514664.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Nat Genet. 1994 Mar;6(3):217-9 [8012377.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Cell. 2000 Oct 13;103(2):311-20 [11057903.001]
  • (PMID = 15767571.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA110057; United States / NCI NIH HHS / CA / CA90658; United States / NCI NIH HHS / CA / R01 CA080003; United States / NCI NIH HHS / CA / R03 CA110057; United States / NCI NIH HHS / CA / CA80003; United States / NCI NIH HHS / CA / R01 CA090658
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bub1b protein, mouse; 0 / Cell Cycle Proteins; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC555497
  •  go-up   go-down


Advertisement
4. Chow E, Lipton L, Lynch E, D'Souza R, Aragona C, Hodgkin L, Brown G, Winship I, Barker M, Buchanan D, Cowie S, Nasioulas S, du Sart D, Young J, Leggett B, Jass J, Macrae F: Hyperplastic polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology; 2006 Jul;131(1):30-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Hyperplastic polyposis syndrome (HPS) is defined phenotypically with multiple, large and/or proximal hyperplastic polyps.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. DNA Glycosylases / genetics. DNA, Neoplasm / genetics. Endodeoxyribonucleases / genetics. Germ-Line Mutation
  • [MeSH-minor] Adult. Aged. Alleles. Biopsy. Colonoscopy. Female. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree. Phenotype. Polymerase Chain Reaction

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831587.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 3.1.- / Endodeoxyribonucleases; EC 3.1.- / MBD4 protein, human; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


5. Lee EJ, Park CK, Kim JW, Chang DK, Kim KM: Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis. APMIS; 2007 Aug;115(8):982-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis.
  • BRAF gene mutations in the colorectum have been associated with serrated adenomas and less frequently with hyperplastic polyps, villous adenomas, tubular adenomas, and carcinomas.
  • We report a case with a very rare deletion mutation of BRAF (c.1799-1801delTGA, p.Val600_Lys601delinsGlu) in a serrated adenoma; the patient has familial adenomatous polyposis with a germline mutation of the APC gene (c.3578delA, p.Gln1193ArgfsX1264).
  • Genetic studies on fundic gland polyps and tubular adenomas from the same patient failed to demonstrate BRAF mutation.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Gene Deletion. Proto-Oncogene Proteins B-raf / genetics

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696956.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


6. Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellié C, Laurent-Puig P, members of the ANGH group: Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer; 2006;6:270
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma.
  • To document the role of MMP polymorphisms in the early step of colorectal carcinogenesis, we investigated their association with colorectal adenoma risk in a case-control study comprising 295 patients with large adenomas (LA), 302 patients with small adenomas (SA) and 568 polyp-free (PF) controls.
  • RESULTS: No association was observed between the polymorphisms and LA when compared to PF or SA.
  • When comparing SA to PF controls, analysis revealed a significant association between MMP3 -1612 ins/delA polymorphism and SA with an increased risk associated with the 6A/6A genotype (OR = 1.67, 95% CI: 1.20-2.34).
  • CONCLUSION: These data show a relation between MMP1 -1607 ins/del G and MMP3 -1612 ins/delA combined polymorphisms and risk of SA, suggesting their potential role in the early steps of colorectal carcinogenesis.
  • [MeSH-major] Adenomatous Polyps / genetics. Colorectal Neoplasms / genetics. Matrix Metalloproteinase 1 / genetics. Matrix Metalloproteinase 3 / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Can J Physiol Pharmacol. 1999 Jul;77(7):465-80 [10535707.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1600-5 [10845878.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1215-21 [10971431.001]
  • [Cites] Mod Pathol. 2000 Sep;13(9):925-33 [11007031.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):623-9 [11102751.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20108-15 [11274170.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2344-6 [11489811.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1834-9 [11701474.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3855-60 [12097300.001]
  • [Cites] Int J Cancer. 2002 Dec 10;102(5):526-9 [12432557.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Am Coll Cardiol. 2003 Jun 18;41(12):2130-7 [12821236.001]
  • [Cites] J Pathol. 2003 Aug;200(5):568-76 [12898592.001]
  • [Cites] Genet Epidemiol. 2003 Sep;25(2):158-67 [12916024.001]
  • [Cites] Clin Chem. 2003 Nov;49(11):1940-2 [14578330.001]
  • [Cites] Int J Cancer. 1991 Nov 11;49(5):666-72 [1657796.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 15;201(2):657-64 [8002999.001]
  • [Cites] Mol Carcinog. 1994 Aug;10(4):199-206 [8068180.001]
  • [Cites] Cancer. 1995 Mar 15;75(6 Suppl):1516-9 [7889484.001]
  • [Cites] Int J Cancer. 1995 Apr 10;61(2):218-22 [7705951.001]
  • [Cites] Br Heart J. 1995 Mar;73(3):209-15 [7727178.001]
  • [Cites] Transplantation. 1995 Aug 27;60(4):375-83 [7652768.001]
  • [Cites] Nat Med. 1996 Apr;2(4):461-2 [8597958.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13055-60 [8662692.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1255-64 [8918435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1402-7 [9037065.001]
  • [Cites] Mol Carcinog. 1997 Aug;19(4):225-9 [9290698.001]
  • [Cites] Atherosclerosis. 1998 Jul;139(1):49-56 [9699891.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5321-5 [9850057.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4225-7 [10485461.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):594-9 [15701845.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):892-9 [15695237.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Jul 1;24(1):101-9 [16803608.001]
  • [Cites] J Pathol. 2003 Dec;201(4):528-34 [14648655.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17 [15000152.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2594-9 [15102660.001]
  • [Cites] Am J Hum Genet. 2004 Oct;75(4):561-70 [15290652.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:936-9 [4853883.001]
  • [Cites] J Chronic Dis. 1982;35(5):313-20 [7068807.001]
  • [Cites] Int J Cancer. 1986 Dec 15;38(6):789-94 [3793259.001]
  • [Cites] Oncogene. 1999 Dec 20;18(55):7908-16 [10630643.001]
  • (PMID = 17125518.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.7 / Matrix Metalloproteinase 1
  • [Other-IDs] NLM/ PMC1687194
  •  go-up   go-down


7. Loh K, Chia JA, Greco S, Cozzi SJ, Buttenshaw RL, Bond CE, Simms LA, Pike T, Young JP, Jass JR, Spring KJ, Leggett BA, Whitehall VL: Bone morphogenic protein 3 inactivation is an early and frequent event in colorectal cancer development. Genes Chromosomes Cancer; 2008 Jun;47(6):449-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Methylation was also frequently observed in serrated and traditional adenomatous polyps (22/29, 76%).
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Adenoma / genetics. Adenoma / metabolism. Bone Morphogenetic Protein 3. Cell Line, Tumor. Cohort Studies. Colonic Polyps / genetics. Colonic Polyps / metabolism. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / metabolism. CpG Islands. Disease Progression. Humans. Intestinal Mucosa / metabolism. Loss of Heterozygosity. Microsatellite Instability. Nuclear Proteins / genetics. Precancerous Conditions / genetics. Precancerous Conditions / metabolism. Promoter Regions, Genetic / genetics. Subtraction Technique. Tumor Stem Cell Assay


8. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K: Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol; 2006 Mar 7;12(9):1336-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After performing a randomized study for polyp chemoprevention study in patients with familial adenomatous polyposis (FAP),which showed that the treatment with celecoxib, one of the coxibs, significantly reduced the number of colorectal polyps in 2000, the U.S.
  • [MeSH-minor] Adenomatous Polyposis Coli / drug therapy. Cardiovascular Diseases / chemically induced. Cardiovascular Diseases / physiopathology. Cell Proliferation / drug effects. Colorectal Neoplasms / etiology. Colorectal Neoplasms / prevention & control. Cyclooxygenase 2 Inhibitors / adverse effects. Cyclooxygenase 2 Inhibitors / pharmacology. Cyclooxygenase 2 Inhibitors / therapeutic use. Dinoprostone / metabolism. Esophageal Neoplasms / etiology. Esophageal Neoplasms / prevention & control. Humans. Intestinal Mucosa / chemistry. Intestinal Mucosa / metabolism. RNA, Messenger / analysis. Risk Factors. Stomach Neoplasms / etiology. Stomach Neoplasms / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2002 Mar;8(3):289-93 [11875501.001]
  • [Cites] J Natl Cancer Inst. 2002 Mar 20;94(6):422-9 [11904314.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):60-7 [12105834.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1351-9 [12151354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 20;299(5):886-90 [12470662.001]
  • [Cites] J Gastroenterol. 2002;37(11):896-904 [12483244.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):250-3 [12532441.001]
  • [Cites] Digestion. 2002;66(4):222-9 [12592098.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):133-8 [15221998.001]
  • [Cites] Dig Dis Sci. 2004 Jun;49(6):948-53 [15309882.001]
  • [Cites] World J Gastroenterol. 2004 Oct 1;10(19):2809-13 [15334675.001]
  • [Cites] Nat New Biol. 1971 Jun 23;231(25):232-5 [5284360.001]
  • [Cites] Ann Surg. 1992 Jul;216(1):35-43 [1632700.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6735-40 [1458460.001]
  • [Cites] Carcinogenesis. 1992 Dec;13(12):2313-6 [1473239.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Ann Surg. 1995 Oct;222(4):525-31; discussion 531-3 [7574932.001]
  • [Cites] Cell. 1995 Nov 3;83(3):345-8 [8521461.001]
  • [Cites] Cell. 1995 Nov 3;83(3):493-501 [8521479.001]
  • [Cites] Int J Cancer. 1996 Jul 17;67(2):269-74 [8760598.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4566-9 [8840961.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):179-83 [8931116.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Dec;15(12):1386-92 [11197048.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):26-30 [11223821.001]
  • [Cites] J Biol Chem. 1996 Dec 27;271(52):33157-60 [8969167.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1276-80 [9102213.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336-40 [9096394.001]
  • [Cites] Jpn J Cancer Res. 1997 Nov;88(11):1044-51 [9439679.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):409-12 [9458081.001]
  • [Cites] Jpn J Cancer Res. 1997 Dec;88(12):1117-20 [9473726.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):G1061-7 [9696706.001]
  • [Cites] J Biol Chem. 1998 Oct 30;273(44):28560-3 [9786845.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 21;90(20):1529-36 [9790545.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1609-20 [9811310.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):961-8 [12631593.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):674-7 [12679908.001]
  • [Cites] Cancer Res. 2003 Jun 15;63(12):3032-6 [12810622.001]
  • [Cites] J Clin Gastroenterol. 2003 Jul;37(1):28-33 [12811205.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6726-34 [14583467.001]
  • [Cites] APMIS. 2003 Oct;111(10):915-25 [14616542.001]
  • [Cites] Dis Esophagus. 2003;16(3):177-86 [14641306.001]
  • [Cites] Gut. 2004 Feb;53(2):195-200 [14724149.001]
  • [Cites] EMBO J. 2004 Apr 7;23(7):1669-78 [15014433.001]
  • [Cites] Carcinogenesis. 1998 Nov;19(11):1939-42 [9855006.001]
  • [Cites] J Clin Gastroenterol. 1998;27 Suppl 1:S47-52 [9872498.001]
  • [Cites] Carcinogenesis. 1998 Dec;19(12):2195-9 [9886578.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):198-204 [9892207.001]
  • [Cites] Am J Gastroenterol. 1999 Feb;94(2):451-5 [10022645.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):965-8 [10425287.001]
  • [Cites] Int J Cancer. 1999 Aug 20;84(4):400-3 [10404093.001]
  • [Cites] Clin Cancer Res. 2004 Dec 1;10(23):8105-13 [15585646.001]
  • [Cites] World J Gastroenterol. 2005 Jan 7;11(1):41-5 [15609394.001]
  • [Cites] Arch Intern Med. 2005 Jan 24;165(2):181-6 [15668364.001]
  • [Cites] Ann Intern Med. 2005 Feb 1;142(3):157-64 [15684203.001]
  • [Cites] Carcinogenesis. 2005 Mar;26(3):565-70 [15564290.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Apr;14(4):359-63 [11943946.001]
  • [Cites] Curr Pharm Des. 2002;8(12):1021-34 [11945149.001]
  • [Cites] Science. 2002 Apr 19;296(5567):474-5 [11964462.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8022-7 [16140976.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1274-9 [10604722.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):293-7 [10667579.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):519-25 [10690533.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):487-96 [10702199.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):953-8 [10783317.001]
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):95-100 [10861458.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):729-35 [10980112.001]
  • [Cites] JAMA. 2000 Sep 13;284(10):1247-55 [10979111.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5767-72 [11059772.001]
  • [Cites] N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528 [11087881.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1733-40 [11245490.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):547-51 [11285187.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):609-15 [11304699.001]
  • [Cites] Am J Gastroenterol. 2001 Apr;96(4):990-6 [11316217.001]
  • [Cites] Br J Cancer. 2001 May 18;84(10):1412-6 [11355956.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1923-31 [11448905.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6131-6 [11507063.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):2998-3005 [11595687.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1391-9 [11729118.001]
  • [Cites] J Pathol. 2002 Feb;196(2):171-9 [11793368.001]
  • (PMID = 16552798.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / RNA, Messenger; EC 1.14.99.1 / Cyclooxygenase 2; K7Q1JQR04M / Dinoprostone
  • [Number-of-references] 92
  • [Other-IDs] NLM/ PMC4124307
  •  go-up   go-down


9. Summers RM, Handwerker LR, Pickhardt PJ, Van Uitert RL, Deshpande KK, Yeshwant S, Yao J, Franaszek M: Performance of a previously validated CT colonography computer-aided detection system in a new patient population. AJR Am J Roentgenol; 2008 Jul;191(1):168-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A computer-aided detection (CAD) system with high sensitivity in the detection of adenomatous polyps in varied CT colonography (CTC) data sets increases the utility of CAD in the clinical setting.
  • Most of the patients were at average risk, had CTC findings suggestive of polyps, and underwent colonoscopy.
  • In a previous non-polyp-enriched screening cohort, the standalone performance of the CAD system was 93.3% (28/30) sensitivity for adenomatous polyps 10 mm or larger, 51.1% (47/92) sensitivity for adenomas 6-9 mm, and a mean false-positive rate of 8.6 per patient.
  • RESULTS: The CAD system had per-polyp sensitivities of 91.5% (43/47; 95% CI, 78.7-97.2%; p = 1.0) for adenomas 10 mm or larger and 82.1% (32/39; 65.9-91.9%; p = 0.0009) for adenomas 6-9 mm.
  • CONCLUSION: The CAD system evaluated has a high level of performance in the detection of adenomatous polyps with CTC data from a polyp-enriched cohort different from that used to train the system.
  • [MeSH-major] Artificial Intelligence. Colonic Polyps / radiography. Colonography, Computed Tomographic / methods. Colorectal Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18562741.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Intramural; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


10. Grünhage F, Jungck M, Lamberti C, Berg C, Becker U, Schulte-Witte H, Plassmann D, Rahner N, Aretz S, Friedrichs N, Buettner R, Sauerbruch T, Lammert F: Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int J Colorectal Dis; 2008 Feb;23(2):147-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to identify genetic factors for familial CRC (fCRC) in a unique study design that includes phenotypic extremes as represented by fCRC cases and 'hyper-normal' controls without CRC history and no adenomatous polyps on colonoscopy.
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Colonoscopy. Female. Gene Frequency. Genetic Predisposition to Disease. Heterozygote. Homozygote. Humans. Male. Middle Aged. Odds Ratio. Pedigree. Phenotype. Promoter Regions, Genetic. Prospective Studies. Risk Assessment


11. Obrador A: Fibre and colorectal cancer: a controversial question. Br J Nutr; 2006 Aug;96 Suppl 1:S46-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a few intervention trials have not demonstrated the preventive role of dietary fibre on the occurrence of adenomatous colorectal polyps.
  • [MeSH-minor] Adenoma / prevention & control. Animals. Case-Control Studies. Cohort Studies. Diet. Humans. Models, Animal


12. Kovács M, Pák P, Pák G, Fehér J: [Screening and surveillance for hereditary polyposis and non-polyposis syndromes with capsule endoscopy]. Orv Hetil; 2008 Apr 6;149(14):639-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Earlier the diagnosis of these symptoms was difficult to establish because traditional radiological methods have a low yield for small polyps.
  • As the results compared of the diagnosed familial adenomatous polyposis and of Peutz-Jeghers syndrome reflect on capsule endoscopy, its diagnostic sensitiveness is stated as significantly higher than the Barium-contrast X-Ray and MR-enterography.
  • Nevertheless, determination of size and location of polyps has become more problematic when evaluating the test results.
  • [MeSH-major] Adenomatous Polyposis Coli / diagnosis. Capsule Endoscopy. Colorectal Neoplasms / prevention & control. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Mass Screening / methods. Peutz-Jeghers Syndrome / diagnosis. Population Surveillance / methods
  • [MeSH-minor] Humans. Intestinal Polyps / diagnosis. Intestinal Polyps / genetics. Intestinal Polyps / prevention & control. Magnetic Resonance Imaging. Syndrome. Tomography, X-Ray Computed. Video Recording

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18375363.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Hungary
  • [Number-of-references] 42
  •  go-up   go-down


13. Neneman B, Gasiorowska A, Małecka-Panas E: The efficacy and safety of argon plasma coagulation (APC) in the management of polyp remnants in stomach and colon. Adv Med Sci; 2006;51:88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of argon plasma coagulation (APC) in the management of polyp remnants in stomach and colon.
  • PURPOSE: Endoscopic treatment of sessile and semipedunculated polyps remains controversial.
  • The aim of the study was to assess the outcome and safety of argon plasma coagulation (APC) in the management of gastric and colorectal polyp remnants after polypectomy, and to search for clinical parameters useful in predicting the efficacy of this technique.
  • MATERIAL AND METHODS: This prospective study comprised 18 patients with gastric polyps and 29 with colonic polyps found in upper and lower GI endoscopy.
  • Overall 22 gastric polyps and 58 colonic polyps have been detected.
  • All those polyps were removed at colonoscopy with the diathermic snare and the polyp remnants were destroyed with APC using Argon Beamer source (Erbe, Germany).
  • RESULTS: Pathologic examination revealed 10 hyperplastic polyps and 12 tubular adenomas of the stomach.
  • Effective destruction of polyp remnants was achieved in 20 (90.9%) gastric polyps in 16 (88.9%) patients.
  • Significant positive correlation was demonstrated between the power output, APC sessions number and polyp location in the prepyloric part, its size and adenomatous content.
  • Among colonic polyps there were: 17 hyperplastic, 26 tubular, 8 tubulo-villous, 4 villous adenomas and 3 inflammatory pseudopolyps.
  • Effective destruction of remnant polyp tissue was obtained in 56 (96.4%) polyps in 27 (93.1%) patients.
  • A significant positive correlation between the power output and the size, distal location and villous texture of the polyp has been demonstrated.
  • CONCLUSIONS: APC is an effective and safe method in the management of polyp remnants in the stomach and colon.
  • The application of higher electric power and numerous APC sessions are necessary to remove residues of large gastric polyps located in the prepyloric part and of with adenomatous content.
  • In the case of colonic polyps the application of higher electric power should be recommended in case of large-sized lesions, located in rectum and of villous texture.
  • [MeSH-major] Colonic Polyps / surgery. Electrocoagulation / methods. Neoplasm, Residual / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adult. Aged. Argon / therapeutic use. Colonoscopy. Endoscopy. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. Argon, Elemental .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357283.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  •  go-up   go-down


14. Heiken JP: CT colonography screening: ready for prime time? Cancer Imaging; 2009;9 Spec No A:S59-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although multiple prospective randomized trials and observational studies have demonstrated that mortality from colon cancer can be reduced with screening and removal of adenomatous polyps, compliance with screening guidelines remains low.
  • Recent CT colonography (CTC) trials have shown that CTC is capable of demonstrating adenomatous polyps > or =10 mm (and in most cases > or = 6 mm) with sensitivities comparable to those for optical colonoscopy.
  • [MeSH-major] Adenocarcinoma / radiography. Adenoma / radiography. Colonic Neoplasms / radiography. Colonic Polyps / radiography. Colonography, Computed Tomographic
  • [MeSH-minor] Adenomatous Polyps / radiography. Aged. Colonoscopy / adverse effects. Expert Testimony. Humans. Insurance Coverage. Mass Screening. Medicaid. Medicare. Middle Aged. Multicenter Studies as Topic. Patient Compliance. Practice Guidelines as Topic. Randomized Controlled Trials as Topic / statistics & numerical data. Sensitivity and Specificity. United States

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1296-308 [12094842.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 5;95(3):230-6 [12569145.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):911-6 [12671887.001]
  • [Cites] Eur Radiol. 2003 Jun;13(6):1297-302 [12764645.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] JAMA. 2004 Apr 14;291(14):1713-9 [15082698.001]
  • [Cites] Cancer. 2004 May 15;100(10):2093-103 [15139050.001]
  • [Cites] Radiology. 2004 Aug;232(2):611-20 [15215541.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):653-7 [1736103.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1467-71 [8942774.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] Am J Med. 1999 Jan 25;106(1A):7S-10S [10089107.001]
  • [Cites] Lancet. 2005 Jan 22-28;365(9456):305-11 [15664225.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):409-16 [15734966.001]
  • [Cites] Radiology. 2005 Aug;236(2):519-26 [16040909.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2771-6 [16393234.001]
  • [Cites] AJR Am J Roentgenol. 2006 Mar;186(3):718-28 [16498099.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Radiology. 2006 May;239(2):457-63 [16543590.001]
  • [Cites] Radiology. 2006 May;239(2):464-71 [16569789.001]
  • [Cites] Radiology. 2006 May;239(2):313-6 [16641348.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2213-21 [17455218.001]
  • [Cites] N Engl J Med. 2007 Oct 4;357(14):1403-12 [17914041.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jan;190(1):136-44 [18094303.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Radiology. 2008 Oct;249(1):151-9 [18796673.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1207-17 [18799557.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1100-5 [18691580.001]
  • [Cites] Ann Intern Med. 2008 Nov 4;149(9):627-37 [18838716.001]
  • [Cites] Gut. 2009 Feb;58(2):241-8 [18852257.001]
  • [Cites] Radiology. 2000 May;215(2):353-7 [10796907.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):1121-2; author reply 122-3 [19167389.001]
  • [Cites] Am J Gastroenterol. 2009 Mar;104(3):739-50 [19240699.001]
  • [Cites] Am J Prev Med. 2009 Jul;37(1):8-16 [19442479.001]
  • [Cites] JAMA. 2009 Jun 17;301(23):2453-61 [19531785.001]
  • [Cites] Radiology. 2002 Jul;224(1):25-33 [12091658.001]
  • (PMID = 19965295.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Lectures
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2797457
  •  go-up   go-down


15. McKenzie S, Baek JH, Wakabayashi M, Garcia-Aguilar J, Pigazzi A: Totally laparoscopic right colectomy with transvaginal specimen extraction: the authors' initial institutional experience. Surg Endosc; 2010 Aug;24(8):2048-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A four-trocar laparoscopic right colectomy with intracorporeal anastomosis was performed for cancer in two cases and for adenomatous polyp in two cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 May;25(5):1699-700 [20972582.001]
  • [Cites] J Obstet Gynaecol Res. 2009 Feb;35(1):113-8 [19215557.001]
  • [Cites] Surg Oncol. 2009 Jun;18(2):111-9 [19101141.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2008 Jun;18(3):345-51 [18503365.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2008 Jun;18(3):294-8 [18574421.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):375-88 [16684081.001]
  • [Cites] Surgery. 2006 Oct;140(4):675-82; discussion 682-3 [17011916.001]
  • [Cites] Ann Surg Oncol. 2009 May;16(5):1316-23 [19224286.001]
  • [Cites] Surg Endosc. 2002 Oct;16(10):1420-5 [12085142.001]
  • [Cites] J Obstet Gynaecol Res. 2005 Aug;31(4):286-90 [16018773.001]
  • [Cites] Surg Oncol. 2009 Jun;18(2):95-103 [19110418.001]
  • [Cites] Surg Endosc. 2008 Mar;22(3):689-92 [17623241.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1120-4 [18481149.001]
  • [Cites] Dis Colon Rectum. 2008 Sep;51(9):1350-5 [18478297.001]
  • [Cites] BJOG. 2009 Feb;116(3):465-6 [19187388.001]
  • [Cites] Surg Endosc. 2008 Dec;22(12):2596-600 [18347858.001]
  • [Cites] Surg Endosc. 2002 Dec;16(12):1691-6 [12140631.001]
  • [Cites] J Hosp Infect. 2008 Jul;69(3):274-82 [18550220.001]
  • (PMID = 20108143.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Penn E, Garrow D, Romagnuolo J: Influence of race and sex on prevalence and recurrence of colon polyps. Arch Intern Med; 2010 Jul 12;170(13):1127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of race and sex on prevalence and recurrence of colon polyps.
  • BACKGROUND: African Americans (AAs) have a higher incidence of colorectal cancer (CRC) and present with more advanced disease compared with whites.
  • An increased prevalence of polyps has also been noted in men regardless of race.
  • We sought to validate these observations and assess whether the increase in CRC in AAs is owing to polyp prevalence or incidence differences vs other factors.
  • Multivariate models were constructed to predict prevalence and incidence of polyps.
  • RESULTS: Of individuals undergoing colonoscopies, 3732 met our study criteria (41.3% male and 29.2% AA); 761 (20.4%) had polyps.
  • Male sex (odds ratio, 1.67; 95% confidence interval [CI], 1.39-2.02) independently predicted polyps but race did not.
  • A random 100-patient sample showed no significant racial difference in the proportion of adenomatous polyps among those with polyps (68.0% white vs 60.0% AA, P = .60).
  • Thirty-five (61.4%) had a polyp recurrence.
  • Adjusting for time to subsequent colonoscopy and other confounders, neither male sex (adjusted hazard ratio, 0.98; 95% CI, 0.43-2.21) nor race (1.89; 0.68-5.24) significantly predicted incidence of recurrent polyps.
  • CONCLUSIONS: In this series, male sex but not race predicted prevalence of polyps.
  • Incidence of recurrent polyps was higher in neither male patients nor AAs, but the power of this analysis is limited.
  • [MeSH-major] Colonic Polyps / ethnology. Ethnic Groups. Mass Screening / methods. Neoplasm Recurrence, Local / ethnology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Arch Intern Med. 2010 Jul 12;170(13):1132-4 [20625019.001]
  • (PMID = 20625018.001).
  • [ISSN] 1538-3679
  • [Journal-full-title] Archives of internal medicine
  • [ISO-abbreviation] Arch. Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


17. Petrick N, Haider M, Summers RM, Yeshwant SC, Brown L, Iuliano EM, Louie A, Choi JR, Pickhardt PJ: CT colonography with computer-aided detection as a second reader: observer performance study. Radiology; 2008 Jan;246(1):148-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two-dimensional transverse views were used for initial polyp detection, while three-dimensional (3D) endoluminal and 2D multiplanar views were available for problem solving.
  • After initial review without CAD, the reader was shown CAD-identified polyp candidates.
  • Polyp location, CT Colonography Reporting and Data System categorization, and reader confidence as to the likelihood of a candidate being a polyp were recorded before and after CAD reading.
  • RESULTS: Use of CAD led to nonsignificant average reader AUC increases of 0.03, 0.03, and 0.04 for patients with adenomatous polyps 6 mm or larger, 6-9 mm, and 10 mm or larger, respectively (P > or = .25); likewise, CAD increased average reader sensitivity by 0.15, 0.16, and 0.14 for those respective groups, with a corresponding decrease in specificity of 0.14.
  • These changes achieved significance for the 6 mm or larger group (P < .01), 6-9 mm group (P < .02), and for specificity (P < .01), but not for the 10 mm or larger group (P > .16).
  • CONCLUSION: Use of CAD led to a significant increase in sensitivity for detecting polyps in the 6 mm or larger and 6-9 mm groups at the expense of a similar significant reduction in specificity.
  • [MeSH-major] Colonic Polyps / radiography. Colonography, Computed Tomographic / methods. Diagnosis, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2007
  • [ErratumIn] Radiology. 2008 Aug;248(2):704
  • (PMID = 18096536.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


18. Geboes K, Ectors N, Geboes KP: Pathology of early lower GI cancer. Best Pract Res Clin Gastroenterol; 2005 Dec;19(6):963-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Macroscopically early colorectal cancer and its precursor lesions present as elevated polyps or non-polypoid flat lesions.
  • [MeSH-minor] Adenomatous Polyposis Coli / pathology. Carcinoma in Situ / diagnosis. Carcinoma in Situ / pathology. Colonic Polyps / pathology. Early Diagnosis. Humans. Inflammatory Bowel Diseases / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338652.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 54
  •  go-up   go-down


19. Baxter N, Rabeneck L: New findings about the risks and limitations of colonoscopy used in the early detection of colorectal cancer. Healthc Q; 2009;12(2):24-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colonoscopy is widely used to detect both colorectal cancer and adenomatous polyps, which may become malignant if left alone.
  • If such a polyp or lesion is detected, it can often be removed during the colonoscopy so that no additional procedures or surgery are needed.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369808.001).
  • [ISSN] 1710-2774
  • [Journal-full-title] Healthcare quarterly (Toronto, Ont.)
  • [ISO-abbreviation] Healthc Q
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


20. Gostjeva EV, Thilly WG: Stem cell stages and the origins of colon cancer: a multidisciplinary perspective. Stem Cell Rev; 2005;1(3):243-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analysis of historical age-specific colorectal cancer rates, present day age-specific colonic adenoma prevalence and the few reports of direct measurements of genetic change in human tissues as a function of age in adults have led to a new set of hypotheses about carcinogenesis.
  • In this hypothesis the slowly growing adenomatous polyps would simply be patches of highly organized juvenile tissue modified by the mechanical constraints of surrounding nongrowing adult tissue.
  • [MeSH-major] Adenomatous Polyps / embryology. Cell Differentiation. Cell Transformation, Neoplastic / metabolism. Colon / embryology. Colonic Neoplasms / embryology. Neoplastic Stem Cells / metabolism

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Top Microbiol Immunol. 1996;213 ( Pt 1):249-69 [8814991.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Br J Cancer. 1957 Jun;11(2):161-9 [13460138.001]
  • [Cites] Science. 1956 Feb 24;123(3191):309-14 [13298683.001]
  • [Cites] Ann N Y Acad Sci. 1975 Aug 22;259:7-16 [54039.001]
  • [Cites] N Engl J Med. 1972 Jun 1;286(22):1178-83 [4623227.001]
  • [Cites] Mutat Res. 1998 May 25;400(1-2):553-78 [9685710.001]
  • [Cites] Adv Cancer Res. 1991;56:161-213 [2028841.001]
  • [Cites] PLoS Biol. 2005 May;3(5):e157 [15839726.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Nucleic Acids Res. 2000 May 1;28(9):E44 [10756211.001]
  • [Cites] Cancer Res. 1964 Oct;24:1544-51 [14234000.001]
  • [Cites] Curr Top Microbiol Immunol. 1968;44:86-99 [4878356.001]
  • [Cites] Br J Cancer. 1954 Mar;8(1):1-12 [13172380.001]
  • [Cites] J Pathol. 1994 Nov;174(3):175-82 [7823250.001]
  • [Cites] Science. 2001 Feb 2;291(5505):843-7 [11225636.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1247-56 [15131784.001]
  • [Cites] Nat Genet. 2003 Jul;34(3):255-9 [12833049.001]
  • [Cites] Br J Cancer. 1953 Mar;7(1):68-72 [13051507.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jul;51(1):1-28 [15207251.001]
  • [Cites] Cell. 2001 Jun 29;105(7):829-41 [11439179.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1253-6 [15247139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3749-53 [8170982.001]
  • [Cites] PCR Methods Appl. 1992 Aug;2(1):14-20 [1490171.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 19;83(12):862-6 [2061946.001]
  • [Cites] Science. 1976 May 7;192(4239):569-72 [130679.001]
  • [Cites] Cytopathology. 2004 Jun;15(3):148-53 [15165271.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Nature. 1972 Jan 21;235(5334):137-40 [4110535.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3271-5 [12036944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1972-7 [11842191.001]
  • [Cites] J Theor Biol. 1990 Jul 9;145(1):95-122 [2214810.001]
  • [Cites] Stem Cells Dev. 2004 Dec;13(6):579-84 [15684825.001]
  • [Cites] Lancet Oncol. 2002 Aug;3(8):508-13 [12147437.001]
  • [Cites] Hum Pathol. 1992 May;23(5):496-503 [1314776.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] J Math Biol. 2004 Nov;49(5):455-67 [15549309.001]
  • (PMID = 17142861.001).
  • [ISSN] 1550-8943
  • [Journal-full-title] Stem cell reviews
  • [ISO-abbreviation] Stem Cell Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 45
  •  go-up   go-down


21. Ayuso Velasco R, Núñez Núñez R, Moreno Hurtado C, Enríquez Zarabozo E, Cabrera García R, Jiménez Jaén C: [Familial adenomatous polyposis: a follow-up of the extracolonic manifestations]. Cir Pediatr; 2010 Jan;23(1):35-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Familial adenomatous polyposis: a follow-up of the extracolonic manifestations].
  • INTRODUCTION: Total colectomy is the only effective treatment for prophylaxis against colon cancer in patients with familial adenomatous polyposis (FAP).
  • RESULTS: All had multiple polyps in the colon, and mutation of the APC gene.
  • Duodenal polyps were found in two patients--in one by duodenoscopy, and in the other with the video capsule.
  • [MeSH-major] Adenomatous Polyposis Coli / complications

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578576.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


22. von Betzler M: [Early detection of colorectal carcinoma. Pros and cons]. MMW Fortschr Med; 2005 Apr 7;147(14):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using this approach, 20-30% of polyps in the bowel and early cancer stages can be detected and removed as a prophylactic measure.
  • The hereditary nonpolyposis colorectal cancer syndrome (HNPCC) and familial adenomatous polyposis (FAP) yare the most important risk factors for the development of colorectal carcinoma.
  • However, patients with Crohn's disease or ulcerative colitis also have a greatly increased risk and require more intensive bowel cancer prophylaxis.
  • [MeSH-minor] Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli / diagnosis. Adenomatous Polyposis Coli / surgery. Adult. Colectomy. Colitis, Ulcerative / complications. Colonoscopy. Colorectal Neoplasms, Hereditary Nonpolyposis / complications. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Colorectal Neoplasms, Hereditary Nonpolyposis / surgery. Crohn Disease / complications. Female. Germany. Humans. Male. Middle Aged. Occult Blood. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15887679.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 0
  •  go-up   go-down


23. Will OC, Robinson J, Günther T, Phillips RK, Clark SK, Tomlinson I: APC mutation spectrum in ileoanal pouch polyps resembles that of colorectal polyps. Br J Surg; 2008 Jun;95(6):765-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] APC mutation spectrum in ileoanal pouch polyps resembles that of colorectal polyps.
  • BACKGROUND: Ileoanal pouch polyps commonly develop following restorative proctocolectomy in patients with familial adenomatous polyposis (FAP).
  • In FAP adenomas, the relationship between germline and somatic adenomatous polyposis coli (APC) mutations is determined by 'just right' beta-catenin signalling in tumour cells, with respect to the 20-amino acid beta-catenin-binding/degradation repeats (20AARs) in the APC protein.
  • However, the relationship varies, with upper gastrointestinal polyps typically retaining three to four 20AARs and colonic polyps retaining one or two.
  • The aim of this study was to establish the mutational spectrum in ileoanal pouch polyps, to ascertain whether polyp development resembled that typical of small or large bowel.
  • RESULTS: Loss of heterozygosity was rare in pouch polyps except when the germline mutation left one 20AAR.
  • Overall, the combined alleles left two to three 20AARs in 40 of 51 polyps with an identified 'second hit'.
  • This was significantly fewer than in upper gastrointestinal polyps, and more than in colorectal adenomas.
  • CONCLUSION: Tissue environment appears to influence the position of the 'second hit' in pouch polyps and the mutations resemble those of large bowel polyps.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Colonic Pouches. Genes, APC. Germ-Line Mutation / genetics. Intestinal Polyps / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 18418860.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


24. Gleeson FC, Papachristou GI, Riegert-Johnson DL, Boller AM, Gostout CJ: Progression to advanced neoplasia is infrequent in post colectomy familial adenomatous polyposis patients under endoscopic surveillance. Fam Cancer; 2009;8(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression to advanced neoplasia is infrequent in post colectomy familial adenomatous polyposis patients under endoscopic surveillance.
  • BACKGROUND AND STUDY AIMS: Advanced neoplasia may occur in the remaining colon and distal ileum of familial adenomatous polyposis (FAP) patients who have had a prophylactic colon resection.
  • The role of post operative lower GI endoscopic surveillance and management of advanced neoplasia in FAP patients is not well defined.
  • RESULTS: All patients had adenomatous disease identified upon initial endoscopy with advanced neoplasia identified in 6/42 (14%).
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Adenomatous Polyposis Coli / surgery. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / prevention & control. Endoscopy, Gastrointestinal
  • [MeSH-minor] Adenomatous Polyps / etiology. Adenomatous Polyps / surgery. Adolescent. Adult. Child. Colectomy. Disease Progression. Female. Humans. Laser Coagulation / adverse effects. Lasers, Gas. Male. Middle Aged. Prevalence. Retrospective Studies


25. Yang LP, Yang ZL, Tan XG, Miao XY: [Expression of annexin A1 (ANXA1) and A2 (ANXA2) and its significance in benign and malignant lesions of gallbladder]. Zhonghua Zhong Liu Za Zhi; 2010 Aug;32(8):595-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the expression levels of ANXA1 and ANXA2 and elucidate their clinicopathological significance in adenocarcinoma, peritumoral tissues, adenomatous polyp and chronic cholecystitis of gallbladder.
  • METHODS: EnVision(TM) immunohistochemical staining was used to detect the expression of ANXA1 and ANXA2 in paraffin-embedded tissue sections from resected specimens of adenocarcinoma (n = 108), peritumoral tissue (n = 46), adenomatous polyp (n = 15) and chronic cholecystitis (n = 35).
  • RESULTS: The positive rates and scores of ANXA1 and ANXA2 were significantly higher in adenocarcinoma (59.3%, 56.5%; 3.2 ± 0.9, 3.4 ± 0.8) than those in peritumoral tissues (34.8%, 1.1 ± 0.8, P < 0.01; 30.4%, 1.0 ± 0.8, P < 0.01), adenomatous polyp (26.7%, 0.9 ± 0.7, P < 0.05 or P < 0.01; 26.7%, 0.9 ± 0.8, P < 0.05 or P < 0.01) and chronic cholecystitis (17.1%, 0.7 ± 0.9, P < 0.01; 20.0%, 0.8 ± 0.8, P < 0.01).
  • Kaplan-Meier analysis and multivariate Cox regression analysis showed that ANXA1 or ANXA2 was not an independent prognostic predictor in gallbladder adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adult. Aged. Cholecystectomy / methods. Cholecystitis / metabolism. Cholecystitis / pathology. Female. Gallbladder / metabolism. Gallbladder / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122411.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ANXA2 protein, human; 0 / Annexin A1; 0 / Annexin A2
  •  go-up   go-down


26. Harewood GC, Rathore O, Patchett S, Murray F: Assessment of adherence to published surveillance guidelines--opportunity to enhance efficiency of endoscopic practice. Ir Med J; 2008 Sep;101(8):248-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surveillance procedures were classified as: a) Barrett's oesophagus, b) chronic IBD, c) prior adenomatous colorectal polyps and, d) prior surgical resection of colorectal cancer.
  • Of these, 50 of 133 (37.6%) Barrett's patients, 92 of 213 (43.2%) patients with prior colonic polyps, 36 of 48 (75.0%) patients with prior colonic malignancy and 17 of 47 (36.2%) patients for IBD surveillance were scheduled prematurely.
  • [MeSH-minor] Adenomatous Polyposis Coli / diagnosis. Barrett Esophagus / diagnosis. Colorectal Neoplasms / diagnosis. Databases as Topic. Great Britain. Humans. Inflammatory Bowel Diseases / diagnosis. Ireland

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990956.001).
  • [ISSN] 0332-3102
  • [Journal-full-title] Irish medical journal
  • [ISO-abbreviation] Ir Med J
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


27. Bajbouj M, von Weyhern C, Becker V, Seidl S, Ott R, Schatke W, Fend F, Schmid RM, Meining A: True adenomas of the cardia: a case series of 3 patients. Digestion; 2008;77(1):65-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Three patients with polypoid masses at the cardia below the Z-line were submitted to a tertiary referral center for further diagnosis and therapy.
  • In 2 of the 3 cases the final histopathological diagnosis of low-grade adenoma of the cardia could only be established after complete removal of the polypoid masses.
  • It is, therefore, reasonable to completely remove any suspicious lesions by endoscopy not only for therapeutic but also for diagnostic reasons.
  • [MeSH-major] Adenomatous Polyps / pathology. Cardia / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18349540.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


28. Hao Y, Jemal A, Zhang X, Ward EM: Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995–2004 (United States). Cancer Causes Control; 2009 Dec;20(10):1855-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is largely thought to reflect increases in utilization of CRC screening through detection and removal of adenomatous polyps.
  • RESULTS: Among whites, CRC incidence rates decreased significantly from 1998 through 2004 in age ≥ 65, but not in age 50-64 in counties with high uninsured or poverty rates, fewer PCPs, or in nonmetro areas.
  • Among African Americans or Hispanics, rates did not decrease in age 50-64 in general and age ≥ 65 in counties with high poverty rates, low PCP supply, and nonmetro counties (African Americans).
  • Colorectal endoscopic screening rates increased significantly among whites in both age groups, but not among Hispanics (aged 50-64 in general and aged ≥ 65 residing in high poverty counties) or African Americans residing in counties with higher uninsured rates (age 50-64), low PCP supply, high poverty rates, and nonmetro counties (age ≥ 65).
  • CONCLUSIONS: Our results suggest that individuals residing in poorer communities with lower access to medical care have not experienced the reduction in CRC incidence rates that have benefited more affluent communities; these disparities may be related to health care access barriers to colorectal endoscopic screening.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19543799.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Martínez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, Thompson PA: Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. Carcinogenesis; 2007 Sep;28(9):2019-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat intake, preparation methods, mutagens and colorectal adenoma recurrence.
  • We prospectively assessed the relation between type of meat, meat preparation method, doneness, a metric of HCAs and other mutagens and colorectal adenoma recurrence among 869 participants in a chemoprevention trial of ursodeoxycholic acid.
  • Most meat variables assessed were positively but weakly associated with recurrence of any adenoma.
  • Our results support a meat mutagen exposure hypothesis as a potential mechanism for recurrence of clinically significant adenomatous polyps.
  • [MeSH-major] Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Cooking / methods. Meat / analysis. Mutagens / analysis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690112.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-23074; United States / NCI NIH HHS / CA / CA-41108; United States / NCI NIH HHS / CA / CA106269; United States / NCI NIH HHS / CA / CA95060
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Mutagens; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


30. Bouguen G, Manfredi S, Blayau M, Dugast C, Buecher B, Bonneau D, Siproudhis L, David V, Bretagne JF: Colorectal adenomatous polyposis Associated with MYH mutations: genotype and phenotype characteristics. Dis Colon Rectum; 2007 Oct;50(10):1612-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal adenomatous polyposis Associated with MYH mutations: genotype and phenotype characteristics.
  • RESULTS: MYH mutations were identified only in the group of patients with attenuated adenomatous polyposis with ten or more adenomatous polyps.
  • Three patients presented with a family history of adenomatous polyposis in siblings, without vertical transmission.
  • The median number of colorectal adenomatous polyps was 53 without preferential localization.
  • The phenotype of the disease is similar to attenuated familial adenomatous polyposis.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / pathology. DNA Glycosylases / genetics. Mutation / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674103.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases
  •  go-up   go-down


31. Valanzano R, Ficari F, Curia MC, Aceto G, Veschi S, Cama A, Battista P, Tonelli F: Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis. J Surg Oncol; 2007 Jan 1;95(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balance between endoscopic and genetic information in the choice of ileorectal anastomosis for familial adenomatous polyposis.
  • BACKGROUND AND OBJECTIVES: The number of rectal polyps and the site of mutations in the APC (Adenomatous polyposis coli) gene have been used to guide the surgical management in patients with familial adenomatous polyposis (FAP).
  • The number of rectal polyps was assessed preoperatively and every 6-12 months.
  • RESULTS: On the basis of preoperative polyp rectal count we categorized patients as follows: Group I, 5 or fewer adenomas; Group II, 6-9 adenomas; Group III, 10 or more adenomas.
  • Diffuse rectal polyposis was observed in one patient with mutation at exon 9 who had 10 small polyps at time of surgery.
  • Mutation at the 5'-end of APC (codons 144-232), mutation of MYH and unknown APC or MYH mutation were correlated with a low number of polyps both at presentation and follow-up.
  • CONCLUSIONS: In our experience fewer than 10 rectal polyps at presentation can predict a favorable outcome after IRA.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / surgery. Genes, APC. Germ-Line Mutation. Proctoscopy


32. Misikangas M, Tanayama H, Rajakangas J, Lindén J, Pajari AM, Mutanen M: Inulin results in increased levels of beta-catenin and cyclin D1 as the adenomas increase in size from small to large in the Min/+ mouse. Br J Nutr; 2008 May;99(5):963-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To address this issue we fed Min/+ mice with two diets known to lead to different adenoma outcomes: a high-fat control diet (n 15) or a high-fat inulin-enriched (10 % w/w) diet (n 13).
  • To study the effect of diet on cell signalling during adenoma growth, the adenomas of each Min/+ mouse were divided into three size-categories, and the levels of beta-catenin, E-cadherin, cyclin D1 and matrix metalloproteinase-9, which are known to be involved in colon tumorigenesis, were determined.
  • Neither phenomenon was seen in the control group during adenoma growth.
  • Our results suggest that in addition to the number, size, and growth rate of adenomatous polyps, the signalling pattern of the adenomas should also be considered when evaluating preventive dietary strategies.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Cyclin D1 / metabolism. Diet. Inulin / pharmacology. beta Catenin / metabolism
  • [MeSH-minor] Animals. Cadherins / metabolism. Dietary Fats / administration & dosage. Disease Models, Animal. Disease Progression. Mice. Mice, Inbred C57BL. Neoplasm Proteins / metabolism. Signal Transduction / drug effects


33. Helbig C: Chromoendoscopy and its alternatives for colonoscopy: useful in the United States? Rev Gastroenterol Disord; 2006;6(4):209-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors' interpretation of the existing data is that pancolonic chromoendoscopy to detect flat and depressed lesions is not yet proven as a useful and therefore necessary adjunct to routine colonoscopic examination in non-inflammatory bowel disease patients in the United States.
  • Chromoendoscopy, particularly combined with magnification, is very effective in delineating the pit pattern of polyps and in allowing real-time differentiation of adenomatous from non-adenomatous lesions.

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224893.001).
  • [ISSN] 1533-001X
  • [Journal-full-title] Reviews in gastroenterological disorders
  • [ISO-abbreviation] Rev Gastroenterol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents
  • [Number-of-references] 42
  •  go-up   go-down


34. Ma YM, Wu BP, Xia OD: [Expression and significance of interferon-inducible transmembrane protein-1 gene in Peutz-Jeghers syndrome]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):541-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To detect the mRNA and protein expression of interferon-inducible transmembrane protein-1 (IFITM1) in Peutz-Jeghers syndrome (PJS) and investigate the role of IFITM1 in the occurrence, development and carcinogenesis of PJS polyps.
  • METHODS: Reverse transcription-PCR was employed to detect the mRNA expression of IFITM1 in 16 PJS polyp samples, adenomatous polyp tissues, colon adenocarcinoma samples, and normal intestinal mucosal tissues.
  • RESULTS: The IFITM1 mRNA expression was detected in all these tissues, and the expression intensity increased in the order of normal intestinal mucosa, PJS polyp, adenomatous polyp, and colon adenocarcinoma (F=92.704, P=0.000).
  • CONCLUSION: The expression level of IFITM1 is associated with the progression of the carcinogenetic process in PJS polyp, and can be used as a sensitive biomarker for diagnosis and prognostic evaluation of PJS.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, Differentiation. Biomarkers / metabolism. Disease Progression. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Young Adult

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304549.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / leu-13 antigen
  •  go-up   go-down


35. Smith RA, Cokkinides V, Brawley OW: Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin; 2009 Jan-Feb;59(1):27-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this issue, the current ACS guidelines and recent issues are summarized, updates of testing guidelines for early prostate cancer detection and colorectal cancer screening by the United States Preventive Services Task Force are discussed, and the most recent data from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System and the National Health Interview Survey pertaining to participation rates in cancer screening are described.
  • [MeSH-minor] Adenomatous Polyps / diagnosis. Adenomatous Polyps / prevention & control. Adult. Aged. Breast Neoplasms / diagnosis. Breast Neoplasms / prevention & control. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / prevention & control. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / prevention & control. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / prevention & control. Male. Middle Aged. Prevalence. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / prevention & control. United States / epidemiology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / prevention & control

  • International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 American Cancer Society.
  • (PMID = 19147867.001).
  • [ISSN] 0007-9235
  • [Journal-full-title] CA: a cancer journal for clinicians
  • [ISO-abbreviation] CA Cancer J Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


36. Venesio T, Balsamo A, Sfiligoi C, Fuso L, Molatore S, Ranzani GN, Risio M: Constitutional high expression of an APC mRNA isoform in a subset of attenuated familial adenomatous polyposis patients. J Mol Med (Berl); 2007 Mar;85(3):305-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutional high expression of an APC mRNA isoform in a subset of attenuated familial adenomatous polyposis patients.
  • Familial adenomatous polyposis is an inherited condition associated with hundreds to thousands of colorectal adenomas conferring a very high risk of cancer at a young age.
  • In addition to "classical" form, there is also an attenuated polyposis, with fewer than 100 polyps and a delayed age of cancer onset.
  • The disease has been linked to constitutive mutations of either APC tumor suppressor gene, or less frequently, MYH base-excision repair gene.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli Protein / genetics. Gene Expression Regulation, Neoplastic

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hum Genet. 2002 Sep;71(3):625-31 [12145750.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2954-8 [11867715.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):388-98 [10598803.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):419-37 [12600935.001]
  • [Cites] Hum Mutat. 2004 Nov;24(5):370-80 [15459959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10722-7 [9724771.001]
  • [Cites] Genomics. 1995 Aug 10;28(3):589-91 [7490101.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Hum Mutat. 1998;11(3):197-201 [9521420.001]
  • [Cites] Hum Mol Genet. 1993 Mar;2(3):283-7 [8388766.001]
  • [Cites] Trends Genet. 2002 Mar;18(3):123-7 [11858835.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):435-41 [7591245.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):269-70 [9399850.001]
  • [Cites] Hum Genet. 1996 Nov;98(5):528-33 [8882870.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):348-53 [10646887.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):705-10 [8522331.001]
  • [Cites] Int J Cancer. 1997 Mar 17;70(6):644-8 [9096643.001]
  • [Cites] J Med Genet. 2001 Dec;38(12):863-7 [11768390.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):55-8 [11137998.001]
  • [Cites] Hum Mutat. 1997;10(3):201-6 [9298819.001]
  • [Cites] Mol Vis. 2004 Jun 14;10:383-91 [15218453.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2991-5 [8187087.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):488-94 [9012479.001]
  • [Cites] Genomics. 1998 Nov 1;53(3):276-83 [9799593.001]
  • [Cites] Lab Invest. 2003 Dec;83(12):1859-66 [14691304.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3732-4 [7641184.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7144-8 [15273719.001]
  • (PMID = 17143620.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Protein Isoforms; 0 / RNA, Messenger
  •  go-up   go-down


37. Matusiak D, Benya RV: CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J Histochem Cytochem; 2007 Dec;55(12):1257-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, vitamin D precursors do not present toxicity concerns and may be sufficient for CRC chemoprevention or chemotherapy, providing the appropriate enzymes are present in colonic epithelia.
  • We previously showed that CYP27B1 is present at equally high levels in the colon and CRC irrespective of differentiation but was not present in metastases.
  • In this study we used quantitative immunohistochemistry to show that CYP27A1, converting D3 to 25-hydroxycholecalciferol, is present in increasing concentrations in the nuclei of normal colonic epithelia, aberrant crypt foci (ACF), and adenomatous polyps.
  • Similarly, increasing amounts of the deactivating enzyme CYP24 are present in the nuclei of normal colonic epithelia, ACFs, and adenomatous polyps.
  • [MeSH-minor] Adenomatous Polyps / enzymology. Adenomatous Polyps / ultrastructure. Colon / enzymology. Colon / pathology. Colon / ultrastructure. Humans. Immunohistochemistry. Intestinal Mucosa / enzymology. Intestinal Mucosa / ultrastructure. Lymphatic Metastasis. Vitamin D3 24-Hydroxylase

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875655.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-094346
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.14.- / Steroid Hydroxylases; EC 1.14.13.126 / Vitamin D3 24-Hydroxylase; EC 1.14.13.15 / CYP27A1 protein, human; EC 1.14.13.15 / Cholestanetriol 26-Monooxygenase
  •  go-up   go-down


38. von Roon AC, Tekkis PP, Clark SK, Heriot AG, Lovegrove RE, Truvolo S, Nicholls RJ, Phillips RK: The impact of technical factors on outcome of restorative proctocolectomy for familial adenomatous polyposis. Dis Colon Rectum; 2007 Jul;50(7):952-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of technical factors on outcome of restorative proctocolectomy for familial adenomatous polyposis.
  • PURPOSE: This study was designed to assess the impact of technical factors on functional outcomes and complications in patients undergoing restorative proctocolectomy for familial adenomatous polyposis.
  • The incidence of polyps at the anal transitional zone was lower with handsewn than with stapled anastomosis (19 vs. 38 percent; P=0.047).
  • CONCLUSIONS: Restorative proctocolectomy in patients with familial adenomatous polyposis has good functional outcomes and an acceptable rate of complications, which are independent of choice of technique.
  • Handsewn ileoanal anastomosis with mucosectomy seems to reduce the incidence of subsequent neoplasia in the anal transitional zone but does not eliminate the risk of cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / surgery. Proctocolectomy, Restorative / methods


39. Alder AC, Hamilton EC, Anthony T, Sarosi GA Jr: Cancer risk in endoscopically unresectable colon polyps. Am J Surg; 2006 Nov;192(5):644-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer risk in endoscopically unresectable colon polyps.
  • BACKGROUND: The purpose of the current study was to define the rate of underlying malignancy in endoscopically unresectable polyps.
  • METHODS: An institutional review board-approved review identified all patients undergoing colectomy for radiologically identified or endoscopically unresectable polyps between 1997 and 2006.
  • Patients were included if the endoscopic impression and biopsy findings suggested an adenomatous polyp without invasive cancer.
  • The median endoscopic size of polyps was 3.0 cm (range 0.8 to 10 cm).
  • Polyps were most frequently proximal to the splenic flexure (72%).
  • Size of polyp (P = .81) and histologic type (P = .34) were not significantly associated with invasive cancer.
  • Compared with polyps proximal to the splenic flexure, polyps located distally were more likely to harbor malignancy (rate; P < .02), by both univariate and multivariate analysis (odds ratio [OR] 1.38 [95% confidence interval 1.07 to 1.8]).
  • CONCLUSION: The cancer risk in polyps deemed inappropriate for endoscopic resection was lower than previously reported.
  • Neither polyp size nor histologic type appeared to be significantly associated with invasive cancer.
  • Location of an endoscopically unresectable polyp distal to the splenic flexure confers an increased risk for occult malignancy.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071200.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Sano Y, Ikematsu H, Fu KI, Emura F, Katagiri A, Horimatsu T, Kaneko K, Soetikno R, Yoshida S: Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps. Gastrointest Endosc; 2009 Feb;69(2):278-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps.
  • BACKGROUND: Although microvascular vessels on the surface of colorectal polyps are observed by narrow-band imaging (NBI) with magnification, its clinical usefulness is still uncertain.
  • DESIGN: Prospective polyp study.
  • Patients with polyps >10 mm and those with polyps previously evaluated by histologic examination or colonoscopy were excluded.
  • INTERVENTION: Lesions were classified into 2 groups: polyps with invisible or faintly visible MC vessels as nonneoplastic and polyps with clearly visible MC vessels as neoplastic.
  • RESULTS: Of 92 eligible patients enrolled in this study, 150 lesions, including 39 (26%) hyperplastic polyps and 111 (74%) adenomatous polyps, were detected.
  • Observation of MC vessels detected 107 of 111 neoplastic polyps and 36 of 39 nonneoplastic polyps.
  • CONCLUSION: Observation of surface MC vessels by magnifying NBI is a useful and simple method for differentiating colorectal nonneoplastic and neoplastic polyps.
  • [MeSH-major] Capillaries / pathology. Colonic Polyps / pathology. Colonoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951131.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Bundred NJ, Barnes NL: Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer; 2005 Aug;93 Suppl 1:S10-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cyclooxygenase-2 inhibition reduces the incidence of tumours in animal models, inhibits the development of invasive cancer in colorectal cancer and reduces the frequency of polyps in familial adenomatous polyposis (FAP).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3808-16 [11559718.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18563-9 [11278747.001]
  • [Cites] J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):75-84 [11850210.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):203-12 [11897504.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1676-81 [11912139.001]
  • [Cites] Gut. 2002 Jun;50(6):857-60 [12010890.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1081-6 [12168077.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5405-7 [12359744.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):574-8 [12592372.001]
  • [Cites] Exp Mol Pathol. 2003 Jun;74(3):282-90 [12782016.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2651-6 [12855643.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2645-50 [12860939.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4324-31 [14555502.001]
  • [Cites] Lancet Oncol. 2003 Oct;4(10):605-15 [14554238.001]
  • [Cites] Breast Cancer Res Treat. 2003 Sep;81(2):117-28 [14572154.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1802-10 [14584060.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91 [14693742.001]
  • [Cites] Histopathology. 2004 Jan;44(1):24-8 [14717665.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):591-6 [14688410.001]
  • [Cites] Br J Cancer. 2004 Jan 26;90(2):423-9 [14735188.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):369-75 [14751505.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1631-5 [14985703.001]
  • [Cites] Dis Colon Rectum. 2004 May;47(5):665-73 [15054679.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7 [15217939.001]
  • [Cites] World J Gastroenterol. 2004 Jul 1;10(13):1971-4 [15222049.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):2011-22 [15265936.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] FEBS Lett. 1993 Sep 13;330(2):156-60 [8365485.001]
  • [Cites] Cancer Res. 1995 Sep 1;55(17):3785-9 [7641194.001]
  • [Cites] Biochim Biophys Acta. 1996 Jan 5;1299(1):125-40 [8555245.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] Mol Cell Endocrinol. 1997 Nov 15;134(2):147-56 [9426158.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):987-90 [10070951.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):991-4 [10070952.001]
  • [Cites] Int J Biochem Cell Biol. 1999 May;31(5):551-7 [10399316.001]
  • [Cites] Cancer Lett. 1999 Jun 1;140(1-2):27-35 [10403538.001]
  • [Cites] Lab Invest. 1999 Dec;79(12):1469-77 [10616198.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1306-11 [10728691.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11397-403 [10753955.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1024-8 [10973323.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):632-5 [11830510.001]
  • (PMID = 16100520.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Cyclooxygenase Inhibitors
  • [Number-of-references] 61
  • [Other-IDs] NLM/ PMC2361689
  •  go-up   go-down


42. Worthley DL, Whitehall VL, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt KA, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA: DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene; 2010 Mar 18;29(11):1653-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In all, 88 patients had adenomatous lesions, 32 had proximal serrated polyps (PSPs) and 50 were normal.
  • [MeSH-major] Colorectal Neoplasms / genetics. DNA Methylation. Genetic Predisposition to Disease / genetics. Intestinal Mucosa / metabolism


43. Pacheco TR, Scatena LS, Hoffenberg EJ, Gralla J, Lee LA: Café au lait macules and juvénile polyps. Pediatr Dermatol; 2007 May-Jun;24(3):E17-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Café au lait macules and juvénile polyps.
  • Our objective was to document the prevalence of cutaneous hyperpigmented lesions in children with juvenile polyposis coli or juvenile polyposis coli and their first degree relatives.Children seen in the gastroenterology practice at The Children's Hospital in Denver, Colorado with polyps (juvenile polyposis coli, sporadic juvenile polyps, and familial adenomatous polyposis coli) and their first degree relatives were invited to participate in the study.
  • We found that 8 of 14 patients (eight with juvenile polyposis coli, four with juvenile polyposis, and two with familial adenomatous polyposis coli) had at least one café-au-lait macule, compared with three of 27 relatives (p=0.003).The prevalence of at least one café-au-lait macule in our patients (8/14 or 57.1%, CI: 28.9–82.3%) was significantly higher than the general population prevalence of 28.5% (p=0.023).
  • However, if the two patients with familial adenomatous polyposis coli were excluded, the comparison with the general population prevalence did not reach statistical significance (p=0.095).
  • A notable finding was the presence of multiple café -au-lait macules in 4 of 12 juvenile polyposis coli/juvenile polyposis patients.Two patients with juvenile polyposis coli also had lentigines.
  • In this selected case series, we observed single or multiple café-au-lait macules in a high proportion of children with the three types of polyps.
  • [MeSH-major] Cafe-au-Lait Spots / epidemiology. Intestinal Polyps / epidemiology
  • [MeSH-minor] Adenomatous Polyposis Coli / epidemiology. Adolescent. Adult. Child. Child, Preschool. Colorado / epidemiology. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17509109.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Elitsur Y, Teitelbaum JE, Rewalt M, Nowicki M: Clinical and endoscopic data in juvenile polyposis syndrome in preadolescent children: a multicenter experience from the United States. J Clin Gastroenterol; 2009 Sep;43(8):734-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 366 polyps were removed, of which 90.5% were pedunculated and 9.5% were sessile.
  • Polyps were evenly distributed throughout the colon.
  • Most of the polyps (99.2%) had benign histology (inflammatory changes) and 3 (0.8%) involved focal adenomatous changes.
  • No adenocarcinoma was identified in any of the 366 polyps.
  • CONCLUSIONS: Colonic polyps in JPS are rarely malignant during the pediatric age period.
  • [MeSH-major] Colonic Polyps
  • [MeSH-minor] Adenoma / complications. Adenoma / pathology. Child. Colon / pathology. Colonic Neoplasms / complications. Colonic Neoplasms / pathology. Colonoscopy. Endoscopy. Female. Gastrointestinal Hemorrhage / epidemiology. Gastrointestinal Hemorrhage / pathology. Humans. Male. Precancerous Conditions / complications. Precancerous Conditions / pathology. Syndrome. United States

  • Genetic Alliance. consumer health - Juvenile polyposis syndrome.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407664.001).
  • [ISSN] 1539-2031
  • [Journal-full-title] Journal of clinical gastroenterology
  • [ISO-abbreviation] J. Clin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


45. Erdem L, Akbayir N, Yildirim S, Köksal HM, Yenice N, Gültekin OS, Sakiz D, Peker O: Predictive value of morphologic characteristics in rectosigmoid adenomatous polyps for the probability of synchronous polyps or cancer in the proximal colon. Turk J Gastroenterol; 2005 Dec;16(4):207-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of morphologic characteristics in rectosigmoid adenomatous polyps for the probability of synchronous polyps or cancer in the proximal colon.
  • The necessity of colonoscopy in patients with an adenoma of<or=5 mm found on sigmoidoscopy is controversial.
  • METHODS: Patients found to have rectosigmoid adenomatous polyps on colonoscopy were included in the study.
  • These adenomas were grouped as diminutive (<or=5 mm), small (6-10 mm) or large (>or=11 mm) polyps.
  • These groups were compared regarding the presence of proximal adenoma and advanced proximal neoplasia (>10 mm adenoma and/or villous histology and/or high grade dysplasia or cancer).
  • Polyps found in the rectum and sigmoid colon were considered as distal polyps and polyps other than these were considered as proximal polyps.
  • RESULTS: In this study, of 1124 consecutive patients who underwent colonoscopy between April 1997 and January 2002, 184 (16%) had 258 adenomatous polyps in the rectosigmoid area.
  • The polyps were diminutive (<or=5 mm) in 105, small (6-10 mm) in 46 and large (>or=11 mm) in 33 patients.
  • Forty-one of the patients (39%) with diminutive polyps, 20 of the patients (43%) with small polyps and 19 of the patients (57%) with large polyps had neoplasm in the proximal bowel.
  • The rate of advanced proximal neoplasm was found to be significantly higher in the group with large polyps in the rectosigmoid area than in the groups with small and diminutive polyps (p<0.05).
  • In 104 patients (57%) with polyp(s) in rectum and sigmoid colon, no associated polyp or cancer was encountered in the proximal colon.
  • CONCLUSION: Colonoscopy is indicated when adenomatous polyp, regardless of size, is found on rectosigmoidoscopy performed because of symptoms.
  • [MeSH-major] Adenomatous Polyps / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasms, Multiple Primary. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16547849.001).
  • [ISSN] 1300-4948
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Turkey
  •  go-up   go-down


46. Guillén-Ponce C, Castillejo A, Barberá VM, Pascual-Ramírez JC, Andrada E, Castillejo MI, Guarinós C, Molina-Garrido MJ, Carrato A, Soto JL: Biallelic MYH germline mutations as cause of Muir-Torre syndrome. Fam Cancer; 2010 Jun;9(2):151-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Muir-Torre syndrome is a rare, inherited disease predisposing of gastrointestinal and cutaneous tumours, such as keratoacanthomas and sebaceous gland adenomas.
  • This report describes a man who has multiple adenomatous colon polyps, a gastric cancer, multiple colorectal cancers and sebaceous adenomas caused by biallelic MYH germline mutations.
  • This finding demonstrates that MYH gene analysis should be considered in Muir-Torre families where no mismatch repair gene mutations have been found.

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19998059.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


47. Buchanan DD, Roberts A, Walsh MD, Parry S, Young JP: Lessons from Lynch syndrome: a tumor biology-based approach to familial colorectal cancer. Future Oncol; 2010 Apr;6(4):539-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most common epithelial lesions are the adenoma and the serrated polyp.
  • CRC is also one of the most familial of the common cancers, and just as there are syndromes associated with increased risk of CRC arising in adenomas, there are also syndromes with increased CRC risk associated with serrated polyps.
  • Lynch syndrome CRC arises almost exclusively within adenomatous precursor lesions, in contrast with familial serrated neoplasia where at least half of the cancers develop in serrated polyps.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Familial Colorectal Cancer.
  • Genetic Alliance. consumer health - Lynch syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2008;204(7):431-47 [18541388.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1774-80 [18628431.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Sep;6(9):1011-5 [18558514.001]
  • [Cites] Dig Dis Sci. 1981 Jan;26(1):85-9 [7460710.001]
  • [Cites] Gastrointest Radiol. 1981;6(4):333-5 [7308714.001]
  • [Cites] Am J Surg Pathol. 1987 Apr;11(4):323-7 [3565675.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Fam Cancer. 2008;7(4):281-5 [18176851.001]
  • [Cites] Cancer Lett. 2009 Jan 18;273(2):221-4 [18778891.001]
  • [Cites] Gastroenterology. 2008 Dec;135(6):2014-8 [19013464.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):572-82 [19047896.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2407-8 [19406141.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):404-9 [19540838.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2310-7 [19661090.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1309-13 [11005503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):177-84 [11176066.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):858-66 [11978509.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Am J Gastroenterol. 2004 Sep;99(9):1779-84 [15330918.001]
  • [Cites] Surg Oncol Clin N Am. 2009 Oct;18(4):599-610 [19793568.001]
  • [Cites] Fam Cancer. 2009;8(4):313-23 [19241144.001]
  • [Cites] Dis Colon Rectum. 2009 Dec;52(12):1949-55 [19934914.001]
  • [Cites] Gut. 2010 Aug;59(8):1094-100 [19710031.001]
  • [Cites] Gut. 2000 Jul;47(1):37-42 [10861262.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):323-32 [10930367.001]
  • [Cites] Am J Gastroenterol. 2004 Oct;99(10):2012-8 [15447765.001]
  • [Cites] Pathol Annu. 1977;12 Pt 1:147-70 [917590.001]
  • [Cites] Dis Colon Rectum. 1979 Apr;22(3):152-6 [446245.001]
  • [Cites] Histopathology. 1980 Mar;4(2):155-70 [7358345.001]
  • [Cites] Histopathology. 1988 Dec;13(6):700-2 [2466756.001]
  • [Cites] Lancet. 1995 Nov 4;346(8984):1200-1 [7475662.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] J Pathol. 1996 May;179(1):20-5 [8691339.001]
  • [Cites] J Mol Med (Berl). 1996 Sep;74(9):547-51 [8892060.001]
  • [Cites] Pathology. 1997 Feb;29(1):28-33 [9094174.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62 [9392616.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999 Mar;28(3):327-32 [10067739.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):503-7 [10235578.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2101-4 [15657661.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Mar;3(3):254-63 [15765445.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1069-75 [15793287.001]
  • [Cites] JAMA. 2005 Apr 27;293(16):1979-85 [15855431.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6063-9 [16024606.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7304-10 [16243801.001]
  • [Cites] Endoscopy. 2006 Mar;38(3):266-70 [16528654.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):897-901 [16702367.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Gastroenterology. 2006 Jul;131(1):30-9 [16831587.001]
  • [Cites] World J Gastroenterol. 2006 Aug 21;12(31):4943-50 [16937488.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Br J Cancer. 2006 Nov 6;95(9):1239-43 [17031395.001]
  • [Cites] Gastroenterology. 2006 Nov;131(5):1400-7 [17101316.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2270-3 [17119056.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1491-501 [17122504.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):261-3 [17312298.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):291-9 [17312306.001]
  • [Cites] J Pathol. 2007 Aug;212(4):378-85 [17503413.001]
  • [Cites] Fam Cancer. 2007;6(3):301-10 [17453358.001]
  • [Cites] Semin Oncol. 2007 Oct;34(5):425-7 [17920898.001]
  • [Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):927-46, viii [17996798.001]
  • [Cites] N Z Med J. 2007;120(1266):U2827 [18264196.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):25-46, v [18313538.001]
  • [Cites] Am J Epidemiol. 2008 May 1;167(9):1050-8 [18304959.001]
  • (PMID = 20373868.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA123010; United States / NCI NIH HHS / CA / R01 CA123010-01A1; United States / NCI NIH HHS / CA / U01 CA097735; United States / NCI NIH HHS / CA / 1R01CA123010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Number-of-references] 70
  • [Other-IDs] NLM/ NIHMS207227; NLM/ PMC2896690
  •  go-up   go-down


48. Pedace L, Majore S, Megiorni F, Binni F, De Bernardo C, Antigoni I, Preziosi N, Mazzilli MC, Grammatico P: Identification of a novel duplication in the APC gene using multiple ligation probe amplification in a patient with familial adenomatous polyposis. Cancer Genet Cytogenet; 2008 Apr 15;182(2):130-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel duplication in the APC gene using multiple ligation probe amplification in a patient with familial adenomatous polyposis.
  • Germline mutations in the adenomatous polyposis coli (APC) gene cause familial adenomatous polyposis (FAP), an autosomal dominant disease characterized by hundreds to thousands of adenomatous polyps in the colon and rectum, with progression to colorectal cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Colorectal Neoplasms / genetics. Gene Duplication. Genes, APC. Germ-Line Mutation / genetics. Nucleic Acid Amplification Techniques / methods


49. Matsumoto T, Esaki M, Yanaru-Fujisawa R, Moriyama T, Yada S, Nakamura S, Yao T, Iida M: Small-intestinal involvement in familial adenomatous polyposis: evaluation by double-balloon endoscopy and intraoperative enteroscopy. Gastrointest Endosc; 2008 Nov;68(5):911-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-intestinal involvement in familial adenomatous polyposis: evaluation by double-balloon endoscopy and intraoperative enteroscopy.
  • BACKGROUND: Small-intestinal adenoma occurs in patients with familial adenomatous polyposis (FAP).
  • The incidence and the endoscopic findings of adenoma were compared between the 2 procedures.
  • Phenotypes of FAP and genotypes of adenomatous polyposis coli (APC) were then compared between patients with small-intestinal adenomas and those without.
  • MAIN OUTCOME MEASUREMENT: The prevalence of adenoma.
  • The adenomas occurred predominantly in the jejunum, with a configuration of diminutive polyps in 22 patients.
  • In addition, a DBE detected nonpolypoid adenoma in a patient, and nodular, broad-based protrusion (advanced lesions) in 3 patients, whereas an IOE detected advanced lesions in a patient.
  • Patients with small-intestinal adenoma had more severe duodenal adenomatosis than those patients without small-intestinal adenoma (P < .001).
  • In cases in which APC was analyzed, the prevalence of small-intestinal adenoma was higher in patients with a 3' mutation (100%) than in those with a 5' mutation (44%) and with a negative mutation (42%, P < .02).
  • LIMITATION: Not a prospective randomized study.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Duodenal Neoplasms / pathology. Endoscopy, Gastrointestinal. Jejunal Neoplasms / pathology


50. Perçinel S, Savaş B, Ensari A, Kuzu I, Kuzu MA, Bektaş M, Cetinkaya H, Kurşun N: Mucins in the colorectal neoplastic spectrum with reference to conventional and serrated adenomas. Turk J Gastroenterol; 2007 Dec;18(4):230-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to determine expression of MUC1, MUC2, MUC5AC, and MUC6 through conventional adenoma-carcinoma sequence and polyps involved in the "serrated" pathway of the colorectum using tissue array technique.
  • METHODS: In this study, a total of 172 cases including 100 colorectal polyps [8 hyperplastic polyps, 10 sessile serrated adenomas, 19 tubular, 37 tubulovillous, and 26 villous adenomas], 16 adenomas with intramucosal carcinoma, 28 conventional colorectal cancers, and 28 normal mucosae were examined.
  • Sessile serrated adenomas exhibited the highest MUC5AC expression while adenomatous polyps showed an increase in MUC5AC expression in parallel with neoplastic progression (p<0.001).
  • Hyperplastic polyps seemed to lie between normal mucosa and sessile serrated adenomas in terms of mucin expression, suggesting that they are morphologically and histogenetically linked.
  • CONCLUSIONS: Upregulation of MUC1 and MUC6 through the adenoma-carcinoma sequence together with downregulation of MUC2 and MUC5AC at the neoplastic end of the spectrum seem to follow the steps of malignant transformation.
  • [MeSH-major] Adenoma / metabolism. Colonic Polyps / metabolism. Colorectal Neoplasms / metabolism. Mucins / metabolism


51. Bobe G, Albert PS, Sansbury LB, Lanza E, Schatzkin A, Colburn NH, Cross AJ: Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila); 2010 Jun;3(6):764-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial.
  • We estimated odds ratios and 95% confidence intervals (95% CI) to determine whether serum IL-6 was associated with colorectal adenoma recurrence and flavonol intake and thus may serve as a risk indicator and as a response indicator to dietary flavonols.
  • Serum IL-6 concentrations at baseline, year 1, and year 3 were measured in 872 participants from the intervention arm of the Polyp Prevention Trial, a 4-year trial that examined the effectiveness of a low-fat, high-fiber, high-fruit and vegetable diet on adenoma recurrence.
  • Intake of flavonols, especially of isorhamnetin, kaempferol, and quercetin, was inversely associated with serum IL-6 concentrations (highest versus lowest flavonol intake quartile, 1.80 versus 2.20 pg/mL) and high-risk (OR, 0.51; 95% CI, 0.26-0.98) and advanced adenoma recurrence (OR, 0.17; 95% CI, 0.06-0.50).
  • A decrease in IL-6 concentration during the trial was inversely associated with high-risk (OR, 0.44; 95% CI, 0.23-0.84) and advanced adenoma recurrence (OR, 0.47; 95% CI, 0.19-1.18).
  • Individuals with above median flavonol intake and equal or below median IL-6 change after baseline had the lowest risk of recurrence of high-risk and advanced adenoma.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 AACR.
  • [Cites] Public Health Nutr. 1999 Dec;2(4):565-9 [10656476.001]
  • [Cites] Clin Cancer Res. 2009 Sep 15;15(18):5878-87 [19737943.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] Am J Clin Nutr. 2001 Sep;74(3):387-401 [11522565.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1584-92 [11920517.001]
  • [Cites] Am J Epidemiol. 2002 Jun 15;155(12):1104-13 [12048224.001]
  • [Cites] Arthritis Res. 2002;4 Suppl 3:S233-42 [12110143.001]
  • [Cites] J Cell Physiol. 2003 Jan;194(1):63-70 [12447990.001]
  • [Cites] J Am Diet Assoc. 2004 Mar;104(3):357-66; quiz 491 [14993857.001]
  • [Cites] Clin Diagn Lab Immunol. 2004 Mar;11(2):325-9 [15013983.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):1029-35 [15447916.001]
  • [Cites] J Clin Epidemiol. 1990;43(12):1327-35 [2254769.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):385-92 [9162305.001]
  • [Cites] Nutr Cancer. 1999;34(1):88-99 [10453447.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(7):908-18 [15533892.001]
  • [Cites] Biofactors. 2004;21(1-4):113-7 [15630180.001]
  • [Cites] Biochem Pharmacol. 2005 Feb 1;69(3):395-406 [15652231.001]
  • [Cites] Semin Oncol. 2005 Feb;32(1):24-34 [15726503.001]
  • [Cites] J Immunol Methods. 2005 May;300(1-2):124-35 [15896801.001]
  • [Cites] Br J Pharmacol. 2005 Aug;145(7):934-44 [15912140.001]
  • [Cites] Tumour Biol. 2005 Jul-Aug;26(4):186-94 [16006772.001]
  • [Cites] J Am Coll Nutr. 2005 Oct;24(5):376-84 [16192263.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 [16214925.001]
  • [Cites] Cell Mol Immunol. 2005 Dec;2(6):455-60 [16426496.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Am J Clin Nutr. 2006 Jun;83(6):1369-79 [16762949.001]
  • [Cites] Clin Nutr. 2006 Jun;25(3):466-76 [16698151.001]
  • [Cites] J Nutr. 2007 May;137(5):1244-52 [17449588.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Aug;7(5):459-64 [17691905.001]
  • [Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1993-2001 [17579859.001]
  • [Cites] Cancer Res. 2008 Jan 1;68(1):323-8 [18172326.001]
  • [Cites] Clin Vaccine Immunol. 2008 Jan;15(1):42-8 [18003817.001]
  • [Cites] Trends Mol Med. 2008 Mar;14(3):109-19 [18261959.001]
  • [Cites] J Nutr. 2008 Apr;138(4):753-60 [18356331.001]
  • [Cites] Eur J Cancer. 2008 May;44(7):937-45 [18387296.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1344-53 [18559549.001]
  • [Cites] J Cell Biochem. 2009 Jan 1;106(1):73-82 [19009557.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):215-22 [19124500.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jan;2(1):60-9 [19139019.001]
  • [Cites] Cancer Causes Control. 2009 Feb;20(1):15-26 [18704713.001]
  • [Cites] Cancer Cell. 2009 Feb 3;15(2):103-13 [19185845.001]
  • [Cites] Respir Med. 2009 Mar;103(3):364-72 [19010653.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 18;101(6):363-5 [19276449.001]
  • [Cites] J Immunol Methods. 2000 Feb 21;235(1-2):71-80 [10675759.001]
  • (PMID = 20484173.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NIH HHS / OD / OD08-007; United States / Intramural NIH HHS / / Z99 CA999999; United States / Intramural NIH HHS / / Z99 HD999999; United States / PHS HHS / / 8-007
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Antioxidants; 0 / Biomarkers; 0 / Flavonols; 0 / IL6 protein, human; 0 / Interleukin-6
  • [Other-IDs] NLM/ NIHMS170216; NLM/ PMC2881177
  •  go-up   go-down


52. Johnson JC, Schmidt CR, Shrubsole MJ, Billheimer DD, Joshi PR, Morrow JD, Heslin MJ, Washington MK, Ness RM, Zheng W, Schwartz DA, Coffey RJ, Beauchamp RD, Merchant NB: Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia. Clin Gastroenterol Hepatol; 2006 Nov;4(11):1358-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this pre-validation study was to determine if urinary PGE-M levels can be used as a biomarker to discriminate between healthy patients and those with colorectal disease.
  • METHODS: Urine PGE-M was assessed in a total of 228 patients with CRC, colonic adenomatous polyps, Crohn's disease, and in subjects with no endoscopically detectable disease.
  • Urine PGE-M levels among patients with Crohn's disease (median, 19.85 [IQR, 6.89-90.2]), CRC (median, 14.65 [IQR, 5.94-92.1]), or large adenomas greater than 1 cm in size (median, 18.85 [IQR, 11.9-25.6]) were significantly increased when compared with patients who had either small polyps less than 1 cm in size (median, 9.69 [IQR, 6.41-22.2]), or no polyps (median, 7.05 [IQR, 2.35-24.7]) (P = .0001).
  • [MeSH-minor] Adenoma / diagnosis. Aged. Biomarkers, Tumor. Colonic Polyps / diagnosis. Crohn Disease / diagnosis. Crohn Disease / urine. Cyclooxygenase 2 / metabolism. Female. Humans. Immunohistochemistry. Logistic Models. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996805.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA46413; United States / NIDDK NIH HHS / DK / DK48831; United States / NIDDK NIH HHS / DK / T32 DK007673; United States / NIDDK NIH HHS / DK / DK52334; United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / R01 CA046413; United States / NCI NIH HHS / CA / T32 CA106183; United States / NIGMS NIH HHS / GM / GM15431; United States / NIDDK NIH HHS / DK / DK07673; United States / NIDDK NIH HHS / DK / R01 DK048831; United States / NCI NIH HHS / CA / P01 CA077839; United States / NCI NIH HHS / CA / CA106183; United States / NIGMS NIH HHS / GM / P50 GM015431; United States / NCRR NIH HHS / RR / RR00095; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCRR NIH HHS / RR / M01 RR000095; United States / NCI NIH HHS / CA / CA95103; United States / NIDDK NIH HHS / DK / R01 DK052334; United States / NCI NIH HHS / CA / CA68485; United States / NCI NIH HHS / CA / CA77839; United States / NCI NIH HHS / CA / CA69457
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Prostaglandins; 73303-30-7 / 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


53. Ibrahim OO, Anjorin AS, Afolayan AE, Badmos KB: Pathological characterization of colorectal polyps in Ilorin, Nigeria. Afr J Med Med Sci; 2010 Sep;39(3):215-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological characterization of colorectal polyps in Ilorin, Nigeria.
  • Colorectal polyps especially the adenomas are recognized precursors of colorectal carcinoma.
  • Identification and removal of such polyps before malignant transformation could reduce the burden of colorectal carcinoma.
  • To document the demography and the histopathological types ofcolorectal polyps received by the Department of Pathology of University of Ilorin Teaching Hospital over a period of thirty years.
  • This is a retrospective review of all cases ofcolorectal polyps that were received, processed and had histological diagnosis in our centre between 1979 and 2008 using the request cards and hematoxylin and eosin stained slides.
  • Forty-four cases of colorectal polyps were reviewed constituting 6.7 percent of all colorectal biopsies/resections received in the same period.
  • Seventeen (38.6%) were adenomas, 9 (20.5%) were juvenile polyps, 8 (18.2%) were inflammatory polyps, 4 cases were lipomatous polyps, 3 were leiomatous polyps, and one each of lymphoid polyp, hamartomatous polyp and neurofibromatous polyp.
  • Of the adenomas, 11 (58.8%) were tubular, 5 (29.4%) were villous, 1 (5.9%) was tubulovillous, and one was a villous adenoma with a focus of malignant transformation.
  • Adenomatous polyp is the commonest pathological type ofcolorectal polyps in our centre.
  • This study therefore sets out to review the age and sex distribution, location and morphological characteristics of all cases of colorectal polyps in our centre over the study period.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21416791.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


54. Neumann H, Fry LC, Bellutti M, Malfertheiner P, Mönkemüller K: Double-balloon enteroscopy-assisted virtual chromoendoscopy for small-bowel disorders: a case series. Endoscopy; 2009 May;41(5):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FICE was found to be a helpful method for the evaluation of adenomatous small-bowel polyps and angiodysplasias.
  • Its use for the characterization of celiac and Crohn's disease appears to be limited.
  • [MeSH-minor] Adolescent. Adult. Aged. Angiodysplasia / diagnosis. Angiodysplasia / pathology. Child. Child, Preschool. Color. Equipment Design. Female. Humans. Intestinal Polyps / diagnosis. Intestinal Polyps / pathology. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418402.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Kenney BC, Jain D: Identification of lymphatics within the colonic lamina propria in inflammation and neoplasia using the monoclonal antibody D2-40. Yale J Biol Med; 2008 Sep;81(3):103-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Representative sections of normal colon, inflamed colon, hyperplastic polyps, inflammatory polyps, adenomatous polyps, adenomatous polyps containing intramucosal carcinoma, and invasive colonic adenocarcinomas were subjected to immunohistochemical staining with D2-40.
  • RESULTS: Lymphatics were not identified within the lamina propria of normal colon.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1973 Jan;64(1):51-66 [4683855.001]
  • [Cites] Gastroenterology. 1966 Dec;51(6):994-1003 [5958610.001]
  • [Cites] Aust N Z J Surg. 1981 Oct;51(5):429-33 [6947780.001]
  • [Cites] Br J Surg. 1985 Sep;72(9):698-702 [4041728.001]
  • [Cites] Lancet. 1986 Oct 18;2(8512):904-7 [2876336.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2430-5 [7922996.001]
  • [Cites] J Submicrosc Cytol Pathol. 1998 Oct;30(4):545-53 [9851063.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):385-94 [10027397.001]
  • [Cites] Br J Cancer. 1958 Sep;12(3):309-20 [13596482.001]
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):125-32 [15868440.001]
  • [Cites] J Pathol. 2005 Jun;206(2):170-7 [15846845.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1057-61 [16001629.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1317-23 [16799477.001]
  • [Cites] Eur Surg Res. 2006;38(5):438-44 [16912482.001]
  • [Cites] Dis Colon Rectum. 2007 Jan;50(1):13-21 [17115337.001]
  • [Cites] Dis Colon Rectum. 2007 Mar;50(3):308-14 [17164964.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):250-6 [12538477.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1920-6 [12702584.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1951-60 [12759251.001]
  • [Cites] Lymphology. 2003 Jun;36(2):52-61 [12926829.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):47-50 [14654901.001]
  • [Cites] World J Gastroenterol. 2004 Nov 15;10(22):3261-3 [15484296.001]
  • [Cites] Cancer. 1981 Mar 15;47(6):1424-9 [7226068.001]
  • (PMID = 18827885.001).
  • [ISSN] 1551-4056
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / monoclonal antibody D2-40
  • [Other-IDs] NLM/ PMC2553648
  •  go-up   go-down


56. Paik SS, Jang SM, Jang KS, Lee KH, Choi D, Jang SJ: Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma. Ann Surg Oncol; 2009 Feb;16(2):297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leptin expression was evaluated on the tissue microarray of 44 normal colon mucosal tissues, 44 adenomatous polyps, and 437 colorectal adenocarcinomas by immunohistochemistry.
  • In univariate survival analysis, patients with leptin-positive adenocarcinoma revealed better overall and disease-free survivals (p = 0.032 and p = 0.004, respectively, log-rank test).
  • In multivariate survival analysis with Cox proportional hazards model, leptin expression was an independent prognostic marker of disease-free survival (p = 0.009).
  • We conclude that leptin was gradually expressed during the normal-adenoma-adenocarcinoma sequence, suggesting an association in colorectal carcinogenesis.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Adenomatous Polyps / metabolism. Adenomatous Polyps / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Child. Colon / metabolism. Colon / pathology. Female. Humans. Immunoenzyme Techniques. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Phenotype. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19050975.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Leptin
  •  go-up   go-down


57. Rutter MD: Are adenomatous polyps rare in ulcerative colitis? Aliment Pharmacol Ther; 2005 Jan 1;21(1):98-9; author reply 99-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are adenomatous polyps rare in ulcerative colitis?
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Colitis, Ulcerative / complications

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Aliment Pharmacol Ther. 2004 Apr 15;19(8):879-87 [15080849.001]
  • (PMID = 15644053.001).
  • [ISSN] 0269-2813
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  •  go-up   go-down


58. Sayers I, Allerton R: Uterine carcinosarcoma in a patient with hereditary non-polyposis coli. Clin Oncol (R Coll Radiol); 2008 Mar;20(2):199-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenomatous Polyps / complications. Carcinosarcoma / complications. Carcinosarcoma / surgery. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18065215.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


59. Suehiro Y, Hinoda Y: Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. Cancer Sci; 2008 Jun;99(6):1071-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic changes in aberrant crypt foci and serrated polyps.
  • Serrated adenoma (SA) is a polyp with serrated architecture and dysplasia, and can be subclassified as traditional SA or sessile SA.
  • Sessile SA is thought to be preneoplastic and differs from most lesions in the traditional SA category because of their flat morphology and general lack of cytological dysplasia.
  • Serrated polyps include hyperplastic polyps (HP), SA, and admixed hyperplastic-adenomatous polyps and are considered a morphological continuum encompassing heteroplastic ACF, HP, admixed hyperplastic-adenomatous polyps, and SA.
  • Recent studies have uncovered other developmental pathways including a heteroplastic ACF-HP/SA-carcinoma sequence and a heteroplastic ACF-adenoma-carcinoma sequence.
  • Heteroplastic ACF histopathologically resemble HP and SA.
  • However, adenocarcinoma arising in the setting of colorectal HP or SA, especially in patients with hyperplastic polyposis, has been described.
  • Our goal is to provide a conceptual framework for understanding the heteroplastic ACF-HP/SA-carcinoma sequence.
  • [MeSH-major] Adenoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. Epigenesis, Genetic


61. Oberwalder M, Zitt M, Wöntner C, Fiegl H, Goebel G, Zitt M, Köhle O, Mühlmann G, Ofner D, Margreiter R, Müller HM: SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis; 2008 Jan;23(1):15-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SFRP2 methylation in fecal DNA--a marker for colorectal polyps.
  • The purpose of this study was to clarify whether SFRP2 methylation in fecal DNA can be found in stool of individuals with hyperplastic and adenomatous colorectal polyps.
  • MATERIALS AND METHODS: Patients who were diagnosed with colorectal polyps or showed negative colonoscopy were included in this study.
  • RESULTS: Stool samples from 68 individuals were checked for DNA content; 23% of the samples (6 of 26) from healthy controls, 46% of the samples (6 of 13) from patients with hyperplastic polyps, and 45% of the samples (13 of 29) from patients with adenomas were positive for human DNA.
  • SFRP2 methylation in stool samples was found in none of the healthy controls, in 33% (2 of 6) patients with hyperplastic polyps, and in 46% (6 of 13) patients with adenomas.
  • Statistical analysis revealed that the frequency of SFRP2 methylation increased significantly (P=0.028) from healthy controls to patients with hyperplastic polyps and to patients with adenomas.
  • CONCLUSIONS: In the current study, we report for the first time that SFRP2 methylation in fecal DNA increases significantly from healthy controls to patients with hyperplastic polyps and to patients with adenomas.
  • SFRP2 methylation may serve as a marker for molecular stool-based adenoma and CRC screening.
  • [MeSH-major] Adenomatous Polyps / genetics. Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic. Membrane Proteins / genetics. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Clin Chim Acta. 2002 Jan;315 (1-2):157-68 [11728417.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):337-42 [9516920.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):199-209 [15738983.001]
  • [Cites] Clin Chem. 2003 Jul;49(7):1058-65 [12816901.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Nucleic Acids Res. 2005 Dec 02;33(21):6823-36 [16326863.001]
  • [Cites] World J Gastroenterol. 2006 Nov 28;12(44):7113-7 [17131472.001]
  • [Cites] Nucleic Acids Res. 2000 Apr 15;28(8):E32 [10734209.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] J Pathol. 2001 Sep;195(1):111-34 [11568897.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] Dis Colon Rectum. 1975 Sep;18(6):494-500 [1181151.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7641-5 [14633683.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 1;20(5):507-15 [15339322.001]
  • [Cites] Dis Markers. 2007;23(1-2):51-71 [17325426.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:845-9 [4851945.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):253-66 [12671664.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • (PMID = 17639423.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / SFRP2 protein, human; 9007-49-2 / DNA
  •  go-up   go-down


62. Half E, Arber N: Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother; 2009 Feb;10(2):211-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CRC has a natural history of transition from a precursor lesion, ie adenomatous polyp to cancer, that spans over 10 to 15 years providing an extended opportunity for intervention and cancer prevention.
  • All articles and other referenced materials were retrieved using the keywords "colon cancer", "adenoma", "chemoprevention", "non steroidal anti-inflammatory drugs", "aspirin", "HMG-CoA reductase inhibitors", "bile acids", "Difluoromethylornithine", "hormone replacement therapy", "mesalamine", "curcumin", and "calcium".
  • Currently, only celecoxib is FDA approved for chemoprevention of CRC and only for high-risk patients with Familial Adenomatous Polyposis (FAP).
  • CONCLUSION: Many agents have shown positive results in the field of chemoprevention however, the ideal chemopreventive agent remains to be discovered with great emphasis on need not to harm.
  • [MeSH-major] Adenomatous Polyps / prevention & control. Anticarcinogenic Agents. Colorectal Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19236194.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Anticarcinogenic Agents; 0 / Bile Acids and Salts; 0 / Cyclooxygenase 2 Inhibitors; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • [Number-of-references] 87
  •  go-up   go-down


63. Koehl GE, Spitzner M, Ousingsawat J, Schreiber R, Geissler EK, Kunzelmann K: Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APC(Min/+) mice. Oncogene; 2010 Mar 11;29(10):1553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The adenomatous polyposis coli (APC) gene is mutated in familial adenomatous polyposis.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / genetics. Codon, Nonsense. Intestinal Neoplasms / prevention & control. Ion Channels / metabolism. Sirolimus / pharmacology
  • [MeSH-minor] Animals. Immunosuppressive Agents / pharmacology. Intestinal Polyps / genetics. Intestinal Polyps / metabolism. Intestinal Polyps / prevention & control. Intestines / drug effects. Intestines / metabolism. Intestines / pathology. Intracellular Signaling Peptides and Proteins / antagonists & inhibitors. Intracellular Signaling Peptides and Proteins / metabolism. Mice. Protein-Serine-Threonine Kinases / antagonists & inhibitors. Protein-Serine-Threonine Kinases / metabolism. TOR Serine-Threonine Kinases. Weight Loss / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19966863.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Codon, Nonsense; 0 / Immunosuppressive Agents; 0 / Intracellular Signaling Peptides and Proteins; 0 / Ion Channels; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


64. Simsek BC, Pehlivan S, Karaoglu A: Human telomerase reverse transcriptase expression in colorectal tumors: correlations with immunohistochemical expression and clinicopathologic features. Ann Diagn Pathol; 2010 Dec;14(6):413-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human telomerase reverse transcriptase (hTERT) proteins in colorectal cancer investigated in several studies, but to our knowledge, hTERT expression has not been evaluated in all of colorectal tumors, including hyperplastic polyps (HPs), adenomas, and carcinomas, on paraffin-embedded tissue sections.
  • In this study, hTERT expression was determined in HP (n = 20), adenomatous polyp (AP) (n = 20), colorectal adenocarcinomas (n = 20), and normal mucosa (n = 20) by immunohistochemical method.
  • Thereby, hTERT expression may use the aggressiveness of the colorectal tumors as a marker, but it is not related to clinicopathologic data.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Adenomatous Polyps / metabolism. Colorectal Neoplasms / metabolism. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21074689.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


65. Del Rio P, Crafa P, Papadia C, Dell'Abate P, Franzè A, Franzini G, Campanini N, Sianesi M: Evaluation of CD10 positivity in colorectal polyps in neoplastic transformation. Ann Ital Chir; 2010 Mar-Apr;81(2):121-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of CD10 positivity in colorectal polyps in neoplastic transformation.
  • MATERIALS AND METHOD: We have correlated CD10 positive in carcinomatous polyps with tumour size, grade, patient age and sex, postoperative TNM staging and Asler-Coller classification.
  • We have matched these cases with a control group that showed presence of polypoid adenomatous tissue with mild to moderate dysplasia.
  • RESULTS: We have divided these in a group of 39 cases, characterised by the presence of carcinoma arising in adenomatous polyps, and a control group of 16 cases, characterised by the presence of colorectal polyps with mild to moderate dysplasia.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Colonic Polyps / metabolism. Colonic Polyps / pathology. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Neprilysin / biosynthesis. Rectal Neoplasms / metabolism. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Case-Control Studies. Female. Humans. Intestinal Polyps / metabolism. Intestinal Polyps / pathology. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726390.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


66. Fernández-Suárez A, Cordero Fernández C, García Lozano R, Pizarro A, Garzón M, Núñez Roldán A: Clinical and ethical implications of genetic counselling in familial adenomatous polyposis. Rev Esp Enferm Dig; 2005 Sep;97(9):654-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and ethical implications of genetic counselling in familial adenomatous polyposis.
  • The association of specific genetic disturbances with the development of hereditary cancer helps us to understand the risk of suffering from it, the possibility of an earlier diagnosis, and the treatment and prevention of this disease.
  • Familial adenomatous polyposis (FAP) is a pre-neoplastic syndrome characterized by the presence of hundreds of adenomatous polyps in the colon, which develop into a carcinoma.
  • FAP can be diagnosed using sequencing techniques to detect mutations in the germinal line of the APC (adenomatous polyposis coli) gene.
  • The genetic diagnostic approach in families with FAP, previously followed up in the Gastrointestinal Clinic, has both advantages and disadvantages, and places us nearer the disease and patient.
  • [MeSH-major] Adenomatous Polyposis Coli / prevention & control. Genetic Counseling


67. Smarrito S, Salmon R: [Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report]. Ann Chir; 2005 Jan;130(1):40-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A palpable mass was discovered in the right breast of a 52 years old man, with a history of rectocolic adenomatous polyposis.
  • Coloscopy is indicated in the presence of mammary fibromatosis, to look for associated multiple polyps, confirming the diagnosis of Gardner's syndrome.

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15664376.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


68. Augustyn AM, Wallerstein R: The role of pediatricians in families with a history of familial adenomatous polyposis. Clin Pediatr (Phila); 2009 Jul;48(6):623-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of pediatricians in families with a history of familial adenomatous polyposis.
  • Colon cancer is not an entity that pediatricians routinely confront; however, a family history of colon cancer can have pediatric implications when it is part of familial adenomatous polyposis syndrome.
  • Colonic (multiple intestinal polyps) and extracolonic manifestations (such as hepatoblastoma or brain tumors) can be the presenting features in children.
  • The authors present 2 patients from different families with familial adenomatous polyposis who presented with the extracolonic manifestation of this syndrome and a family history of colon cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Patient Education as Topic. Physician's Role


69. Sarfaty M, Feng S: Choice of screening modality in a colorectal cancer education and screening program for the uninsured. J Cancer Educ; 2006;21(1):43-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenomatous Polyps / diagnosis. Choice Behavior. Colorectal Neoplasms / diagnosis. Health Education. Mass Screening / methods. Medically Uninsured


70. Cardoso J, Molenaar L, de Menezes RX, van Leerdam M, Rosenberg C, Möslein G, Sampson J, Morreau H, Boer JM, Fodde R: Chromosomal instability in MYH- and APC-mutant adenomatous polyps. Cancer Res; 2006 Mar 01;66(5):2514-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal instability in MYH- and APC-mutant adenomatous polyps.
  • Recently, biallelic germ line mutations in the MYH gene were found to be responsible for MYH-associated polyposis (MAP), an autosomal recessive predisposition to multiple colorectal polyps, often indistinguishable from the dominant familial adenomatous polyposis (FAP) syndrome caused by inherited APC mutations.
  • Here, we analyzed MYH- and APC-mutant polyps by combining laser capture microdissection, isothermal genomic DNA amplification, and array comparative genomic hybridization.
  • Up to 80% and 60% of the MAP and FAP polyps showed aneuploid changes, respectively.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Aneuploidy. Chromosomal Instability. Colorectal Neoplasms / genetics. DNA Glycosylases / genetics. Genes, APC. Germ-Line Mutation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510566.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0301154
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


71. Hartman TJ, Yu B, Albert PS, Slattery ML, Paskett E, Kikendall JW, Iber F, Brewer BK, Schatzkin A, Lanza E: Does nonsteroidal anti-inflammatory drug use modify the effect of a low-fat, high-fiber diet on recurrence of colorectal adenomas? Cancer Epidemiol Biomarkers Prev; 2005 Oct;14(10):2359-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Polyp Prevention Trial was designed to evaluate the effects of a high-fiber (18 g/1,000 kcal), high-fruit and -vegetable (3.5 servings/1,000 kcal), low-fat (20% energy) diet on recurrence of adenomatous polyps.
  • Participants > or =35 years of age, with histologically confirmed colorectal adenoma(s) removed in the prior 6 months, were randomized to the intervention or control group.
  • Adenoma recurrence was found in 754 of 1,905 participants and was not significantly different between groups.
  • Among participants who did not use NSAIDs, the intervention was in the protective direction but did not achieve statistical significance (OR, 0.87; 95% CI, 0.69-1.09).
  • The intervention was protective among males who did not use NSAIDs at baseline (OR, 0.71; 95% CI, 0.54-0.94), but not among NSAIDs users (OR, 1.09; 95% CI, 0.74-1.62).
  • These results should be interpreted cautiously given that they may have arisen by chance in the course of examining multiple associations and Polyp Prevention Trial study participants were not randomly assigned to both dietary intervention and NSAID use.
  • Nevertheless, our results suggest that adopting a low-fat, high-fiber diet rich in fruits and vegetables may lower the risk of colorectal adenoma recurrence among individuals who do not regularly use NSAIDs.
  • [MeSH-major] Adenoma / prevention & control. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Colorectal Neoplasms / prevention & control. Dietary Fats / administration & dosage. Dietary Fiber / administration & dosage. Fruit. Neoplasm Recurrence, Local / prevention & control. Vegetables

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16214917.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Dietary Fats
  •  go-up   go-down


72. Grahn SW, Varma MG: Factors that increase risk of colon polyps. Clin Colon Rectal Surg; 2008 Nov;21(4):247-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors that increase risk of colon polyps.
  • Adenomatous polyps are common and factors that increase risk include race, gender, smoking, and obesity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1994 May;85(5):479-84 [8014105.001]
  • [Cites] Cancer Causes Control. 1994 May;5(3):215-20 [8061168.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 2;86(3):192-9 [8283491.001]
  • [Cites] Epidemiology. 1996 May;7(3):275-80 [8728441.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):193-7 [9217029.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):670-80 [9554606.001]
  • [Cites] Scand J Gastroenterol. 1987 Jan;22(1):13-6 [3563406.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2756-8 [16393231.001]
  • [Cites] BMC Gastroenterol. 2006;6:5 [16412216.001]
  • [Cites] Am J Gastroenterol. 2006 Apr;101(4):823-30 [16494591.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1225-31 [16979948.001]
  • [Cites] J Cancer Educ. 2006 Spring;21(1 Suppl):S32-6 [17020499.001]
  • [Cites] Arch Med Res. 2007 Jul;38(5):519-25 [17560457.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):723-8 [17668638.001]
  • [Cites] J Natl Med Assoc. 2007 Jul;99(7):733-48 [17668639.001]
  • [Cites] Gastroenterology. 2008 Feb;134(2):388-95 [18242207.001]
  • [Cites] Lancet. 2008 Feb 16;371(9612):569-78 [18280327.001]
  • [Cites] J Intern Med. 2008 Apr;263(4):336-52 [18312311.001]
  • [Cites] Scand J Gastroenterol. 1991 Jul;26(7):758-62 [1896819.001]
  • [Cites] J Natl Med Assoc. 1991 Aug;83(8):730-2 [1956086.001]
  • [Cites] J Natl Cancer Inst. 1991 Mar 6;83(5):359-61 [1995919.001]
  • [Cites] Am J Public Health. 1991 Jul;81(7):846-9 [2053658.001]
  • [Cites] Gastroenterology. 1989 Sep;97(3):660-4 [2753326.001]
  • [Cites] Dis Colon Rectum. 1988 Apr;31(4):258-60 [3359894.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):327-34 [7847643.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):137-44 [8419236.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):903-10 [9596467.001]
  • [Cites] Adv Exp Med Biol. 1994;366:269-89 [7771258.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2648-54 [14687811.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Apr;28(4):559-67 [14770200.001]
  • [Cites] J Gen Intern Med. 2004 Apr;19(4):332-8 [15061742.001]
  • [Cites] Arch Med Res. 2004 May-Jun;35(3):215-9 [15163462.001]
  • [Cites] Am J Gastroenterol. 2005 Mar;100(3):515-23; discussion 514 [15743345.001]
  • [Cites] Med Clin North Am. 2005 Jul;89(4):771-93 [15925649.001]
  • [Cites] Int J Colorectal Dis. 2006 Apr;21(3):201-8 [15959790.001]
  • [Cites] Ann Hum Biol. 2005 Jul-Aug;32(4):513-24 [16147399.001]
  • [Cites] Cancer. 2005 Dec 15;104(12 Suppl):2940-7 [16276538.001]
  • [Cites] J Nutr Biochem. 2006 Mar;17(3):145-56 [16426829.001]
  • [Cites] Am J Prev Med. 2006 Apr;30(4):320-6 [16530619.001]
  • [Cites] Prev Chronic Dis. 2006 Apr;3(2):A50 [16539791.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3942-53 [16585224.001]
  • [Cites] Gastrointest Endosc. 2006 Nov;64(5):751-9 [17055869.001]
  • [Cites] Arch Intern Med. 2007 Feb 12;167(3):258-64 [17296881.001]
  • [Cites] J Womens Health (Larchmt). 2007 Jan-Feb;16(1):57-65 [17324097.001]
  • [Cites] Dis Colon Rectum. 1999 Mar;42(3):337-42 [10223753.001]
  • [Cites] Jpn J Cancer Res. 1999 Aug;90(8):805-11 [10543250.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):848-56 [11231939.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):725-31 [11440957.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2238-46 [11467659.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3109S-20S [11694656.001]
  • [Cites] Am J Clin Nutr. 2002 Apr;75(4):767-72 [11916766.001]
  • [Cites] Gut. 2002 Aug;51(2):191-4 [12117878.001]
  • [Cites] Ann Intern Med. 2002 Jul 16;137(2):132-41 [12118972.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2002 Sep;5(5):551-9 [12172480.001]
  • [Cites] Am J Gastroenterol. 2002 Aug;97(8):2100-2 [12190183.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1006-11 [14578135.001]
  • [Cites] JAMA. 2003 Dec 10;290(22):2959-67 [14665657.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2523-32 [15505783.001]
  • [Cites] N Engl J Med. 2005 May 19;352(20):2061-8 [15901859.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2082-6 [16172213.001]
  • [Cites] Health Promot Pract. 2005 Oct;6(4):369-78 [16210678.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Aug;3(8):798-805 [16234009.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2749-55 [16393230.001]
  • [Cites] J Clin Gastroenterol. 2007 Mar;41(3):285-90 [17426468.001]
  • [Cites] Cancer Detect Prev. 2007;31(2):161-5 [17433566.001]
  • [Cites] Am J Health Behav. 2007 Sep-Oct;31(5):502-13 [17555381.001]
  • [Cites] Pol Merkur Lekarski. 2007 May;22(131):373-5 [17679371.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1543-6 [17684126.001]
  • [Cites] J Gastroenterol. 2007 Aug;42(8):616-23 [17701124.001]
  • (PMID = 20011435.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780253
  • [Keywords] NOTNLM ; Polyps / epidemiology / risk factors
  •  go-up   go-down


73. Casadesus D: Surgical resection of rectal adenoma: a rapid review. World J Gastroenterol; 2009 Aug 21;15(31):3851-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection of rectal adenoma: a rapid review.
  • Transanal excision (TE), endoscopic transanal resection (ETAR) and transanal endoscopic microsurgery (TEM) can be used to remove adenomatous polyps.
  • [MeSH-major] Adenoma. Anastomosis, Surgical. Rectal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Orv Hetil. 1999 Oct 3;140(40):2215-9 [10540895.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] ANZ J Surg. 2002 Dec;72(12):854-6 [12485218.001]
  • [Cites] World J Surg. 2003 Feb;27(2):197-202 [12616436.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1345-50 [14530673.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Dis Colon Rectum. 2004 Jan;47(1):86-9 [14702647.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1461-3 [12739115.001]
  • [Cites] JSLS. 2004 Apr-Jun;8(2):123-6 [15119655.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):767-72 [15209623.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):569-73 [15103489.001]
  • [Cites] Nouv Presse Med. 1974 May 25;3(21):1365-6 [4848702.001]
  • [Cites] Chirurg. 1977 May;48(5):343-4 [862483.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):788-93 [8330178.001]
  • [Cites] Br J Surg. 1993 Nov;80(11):1401-4 [8252348.001]
  • [Cites] Helv Chir Acta. 1994 Apr;60(4):599-604 [8034540.001]
  • [Cites] Surg Endosc. 1995 Oct;9(10):1106-12 [8553213.001]
  • [Cites] Harefuah. 1995 Oct;129(7-8):236-7, 295 [8549959.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Langenbecks Arch Surg. 1998 Oct;383(5):320-4 [9860223.001]
  • [Cites] Colorectal Dis. 2005 Jan;7(1):47-50 [15606584.001]
  • [Cites] Colorectal Dis. 2005 Mar;7(2):133-7 [15720349.001]
  • [Cites] Chirurg. 2005 Apr;76(4):379-84 [15502890.001]
  • [Cites] Dig Surg. 2005;22(3):182-9; discussion 189-90 [16137996.001]
  • [Cites] Dis Colon Rectum. 2006 Feb;49(2):228-32 [16322965.001]
  • [Cites] Dig Liver Dis. 2006 Mar;38(3):202-7 [16461025.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):795-9 [17032328.001]
  • [Cites] Tech Coloproctol. 2006 Dec;10(4):277-81 [17115311.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):355-62 [11882757.001]
  • (PMID = 19701964.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 41
  • [Other-IDs] NLM/ PMC2731246
  •  go-up   go-down


74. Döbrôssy L, Kovács A, Budai A, Cornides A, Ottó S, Tulassay Z: [The state of the colorectal screening in Hungary: lessons of the pilot programs]. Orv Hetil; 2007 Sep 23;148(38):1787-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Hungary, colorectal cancer is the second most common malignant disease.
  • The compliance was not more than 30-45%.
  • The programmes revealed a great number of adenomatous polyps and early cancers, and in the way, the effectiveness of the method has been proved.


75. Dariusz A, Jochen R: Increased prevalance of colorectal adenoma in patients with sporadic duodenal adenoma. Eur J Gastroenterol Hepatol; 2009 Jul;21(7):816-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased prevalance of colorectal adenoma in patients with sporadic duodenal adenoma.
  • OBJECTIVES: Duodenal adenomas are common in familial adenomatous polyposis (FAP).
  • It is, however, not known whether patients with duodenal adenomas without FAP should undergo routine colonoscopy for detection of colorectal neoplasia.
  • [MeSH-major] Adenoma / epidemiology. Colonic Polyps / epidemiology. Colorectal Neoplasms / epidemiology. Duodenal Neoplasms / epidemiology. Precancerous Conditions / epidemiology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369885.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


76. Trawiński J, Patera J, Stanek-Widera A, Koktysz R, Kozłowski W: [Pathomorphologic diagnostic guidelines for colon polyps]. Pol Merkur Lekarski; 2007 May;22(131):454-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pathomorphologic diagnostic guidelines for colon polyps].
  • Among polypoid laesions of the large bowel the great attention should be payed to Adenomas because of they neoplastic transformation capabilities.
  • In this paper a classification of neoplastic adenomas extended with serrated adenoma and hyperplastic polyps with presence of tubular adenoma structures has been presented.
  • [MeSH-major] Adenoma / pathology. Adenomatous Polyps / pathology. Colonic Polyps / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679394.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 20
  •  go-up   go-down


77. Samuel MS, Suzuki H, Buchert M, Putoczki TL, Tebbutt NC, Lundgren-May T, Christou A, Inglese M, Toyota M, Heath JK, Ward RL, Waring PM, Ernst M: Elevated Dnmt3a activity promotes polyposis in Apc(Min) mice by relaxing extracellular restraints on Wnt signaling. Gastroenterology; 2009 Sep;137(3):902-13, 913.e1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A33(Dnmt3a) mice infrequently develop spontaneous intestinal polyps.
  • Although we observe a requirement for spontaneous loss of heterozygosity of the adenomatous polyposis coli (Apc) gene to trigger tumorigenesis in Apc(Min) mice, lesions in A33(Dnmt3a);Apc(Min) mice frequently retain the wild-type Apc allele.
  • However, epithelia from normal mucosa and polyps of A33(Dnmt3a);Apc(Min) mice show hypermethylation-mediated transcriptional silencing of the Wnt antagonists Sfrp5, and to a lesser extent, Sfrp1 and increased nuclear beta-catenin alongside activation of the Wnt-target gene Axin2/Conductin.
  • CONCLUSIONS: Aberrant activation of the canonical Wnt pathway, either by mono-allelic Apc loss or transcriptional silencing of Sfrp5 is largely insufficient to promote polyposis, but epistatic interactions between these genetic and epigenetic events enables initiation and promotion of disease.
  • [MeSH-major] Adenomatous Polyposis Coli / metabolism. DNA (Cytosine-5-)-Methyltransferase / metabolism. Genes, APC. Intestinal Mucosa / metabolism. Signal Transduction. Wnt Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454286.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gpa33 protein, mouse; 0 / Membrane Glycoproteins; 0 / Wnt Proteins; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A
  •  go-up   go-down


78. Jo WS, Bandipalliam P, Shannon KM, Niendorf KB, Chan-Smutko G, Hur C, Syngal S, Chung DC: Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol; 2005 Oct;3(10):1022-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of polyp number and family history of colon cancer with germline MYH mutations.
  • BACKGROUND & AIMS: Affected individuals with biallelic MYH mutations are believed to display multiple adenomatous polyps without evidence of vertical transmission.
  • Our goal was to determine the detection rate of germline MYH mutations in a high-risk gastrointestinal cancer clinic population by using polyp number as a selection criterion.
  • RESULTS: Among 45 patients with more than 15 adenomatous polyps not diagnosed with familial adenomatous polyposis, 7 (15.6%) had biallelic MYH mutations.
  • When 122 participants from a high-risk gastrointestinal cancer clinic who did not fulfill these criteria were tested, 2 additional patients with biallelic mutations were identified.
  • Both had young-onset colorectal cancer (age, <50 y) with fewer than 15 polyps.
  • CONCLUSIONS: Most individuals with MYH mutations exhibit multiple adenomatous polyps.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234049.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


79. Zhang H, Morgan D, Cecil G, Burkholder A, Ramocki N, Scull B, Lund PK: Biochromoendoscopy: molecular imaging with capsule endoscopy for detection of adenomas of the GI tract. Gastrointest Endosc; 2008 Sep;68(3):520-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Current capsule endoscopy (CE) provides minimally invasive technology for GI imaging but has limited ability to discriminate different types of polyps.
  • DESIGN: Mouse models of adenomas, hyperplactic/lymphoid polyps, and acute or chronic intestinal inflammation were injected intravenously with a cathepsin B-activated probe (Prosense 680).
  • Prosense 680 was not activated by benign or inflammatory lesions.
  • CONCLUSIONS: We demonstrate proof of the principle that biochromoendoscopy-CE combined with molecular probes--provides a novel approach that differentiates adenomas from benign polyps and inflammatory lesions.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2006 Oct;38(10):963-70 [17058158.001]
  • [Cites] Nat Biotechnol. 1999 Apr;17(4):375-8 [10207887.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):27-37 [15654777.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1632-41 [16410303.001]
  • [Cites] Endocrinology. 1997 Feb;138(2):734-40 [9003009.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1285-90 [7992833.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):301-9 [7519824.001]
  • [Cites] Nat Med. 2003 Jan;9(1):123-8 [12514725.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1527-42 [12404228.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):406-14 [11832455.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):925-37 [11231946.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):725-9 [10840312.001]
  • [Cites] Nature. 2000 May 25;405(6785):417 [10839527.001]
  • [Cites] Clin Chim Acta. 2000 Feb 15;291(2):113-35 [10675719.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):489-96 [12748311.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Mar;5(3):319-25 [17368231.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):971-7 [17058159.001]
  • [Cites] Dig Liver Dis. 2004 Aug;36(8):519-22 [15334771.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Biopolymers. 2004;76(5):391-403 [15389488.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [CommentIn] Gastrointest Endosc. 2008 Sep;68(3):528-30 [18760179.001]
  • (PMID = 18499106.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK080283; United States / NIDDK NIH HHS / DK / R21 DK080283-01; United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NIDDK NIH HHS / DK / P30 DK 34987; United States / NIDDK NIH HHS / DK / DK080283-02; United States / NIDDK NIH HHS / DK / R01 DK040247; United States / NIDDK NIH HHS / DK / R21 DK080283-02; United States / NIDDK NIH HHS / DK / DK40247; United States / NIDDK NIH HHS / DK / DK080283-01; United States / NIDDK NIH HHS / DK / DK047769; United States / NIDDK NIH HHS / DK / R01 DK047769
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes; EC 3.4.22.1 / Cathepsin B
  • [Other-IDs] NLM/ NIHMS116277; NLM/ PMC2754293
  •  go-up   go-down


80. Will O, Carvajal-Carmona LG, Gorman P, Howarth KM, Jones AM, Polanco-Echeverry GM, Chinaleong JA, Günther T, Silver A, Clark SK, Tomlinson I: Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer. Gastroenterology; 2007 Feb;132(2):527-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Homozygous PMS2 deletion causes a severe colorectal cancer and multiple adenoma phenotype without extraintestinal cancer.
  • BACKGROUND & AIMS: We report a patient of Indian descent with parental consanguinity, who developed 10 carcinomas and 35 adenomatous polyps at age 23 and duodenal adenocarcinoma at age 25.
  • PMS2 mutations-and perhaps other homozygous mismatch repair mutations-should be considered in any patient presenting with multiple gastrointestinal tumors, since our patient could not be distinguished clinically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis.
  • [MeSH-major] Adenomatous Polyps / genetics. Adenosine Triphosphatases / genetics. Colorectal Neoplasms / genetics. DNA Repair Enzymes / genetics. DNA-Binding Proteins / genetics. Gene Deletion. Homozygote. Intestinal Polyposis / genetics
  • [MeSH-minor] Adenomatous Polyposis Coli / diagnosis. Adult. DNA Glycosylases / genetics. Diagnosis, Differential. Duodenal Neoplasms / genetics. Fatal Outcome. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Mutation. Pedigree. Protein-Serine-Threonine Kinases. Proto-Oncogene Proteins / genetics. Receptors, Transforming Growth Factor beta / genetics. Severity of Illness Index. ras Proteins

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17258725.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Receptors, Transforming Growth Factor beta; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


81. Saad A, Rex DK: Routine rectal retroflexion during colonoscopy has a low yield for neoplasia. World J Gastroenterol; 2008 Nov 14;14(42):6503-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retroflexion was successful in 1411 (93.9%) patients, unsuccessful or not performed because the rectum appeared narrow in 91 (6.1%).
  • Forty patients had a polyp detected in the distal rectal mucosa.
  • Thirty-three were visible in both the forward and retroflexed view (25 hyperplastic, 8 adenomatous).
  • Seven polyps were visualized only by retroflexion (6 hyperplastic sessile polyps, one 4 mm sessile tubular adenoma).
  • Routine rectal retroflexion did not detect clinically important neoplasia after a careful forward examination of the rectum to the dentate line.
  • [MeSH-major] Adenomatous Polyps / diagnosis. Colonoscopy / methods. Intestinal Polyps / diagnosis. Rectal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2007 Jul;133(1):42-7 [17631129.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Aug;23(8 Pt 2):e312-7 [17854422.001]
  • [Cites] Dis Colon Rectum. 2001 Nov;44(11):1706-8 [11711746.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):532-7 [11923767.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1120-1; author reply 1121 [12195205.001]
  • [Cites] Gastrointest Endosc. 2004 Mar;59(3):380-4 [14997135.001]
  • [Cites] Am J Gastroenterol. 1982 Nov;77(11):856-8 [7137139.001]
  • [Cites] J Clin Gastroenterol. 1986 Dec;8(6):658-60 [3805665.001]
  • [Cites] Am Surg. 1999 Jan;65(1):81-5 [9915539.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1429-30 [10364002.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1537-8 [10364021.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):305-6 [10425511.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):144-8 [16377332.001]
  • [Cites] Am J Gastroenterol. 2006 Jul;101(7):1479-83 [16863549.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E175 [17614078.001]
  • [Cites] Gastrointest Endosc. 2008 Apr;67(4):771-3 [18206880.001]
  • [Cites] J Clin Gastroenterol. 2001 Mar;32(3):235-7 [11246352.001]
  • (PMID = 19030202.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2773336
  •  go-up   go-down


82. Kertész E, Túri J, Gyenes V, Vajda A: [Gardner-syndrome: case report]. Fogorv Sz; 2005 Oct;98(5):213-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major symptoms of Gardner-syndrome are described by the authors (multiple osteomas, desmoid tumors, colon polyps with malignant tendency) with a case appearing in their department.
  • [MeSH-minor] Adenomatous Polyposis Coli / diagnosis. Adenomatous Polyposis Coli / surgery. Adult. Colon, Sigmoid / pathology. Early Diagnosis. Female. Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / surgery. Humans. Mandibular Neoplasms / diagnosis. Mandibular Neoplasms / surgery. Osteoma / diagnosis. Osteoma / surgery. Rectum / pathology

  • Genetic Alliance. consumer health - Gardner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315858.001).
  • [ISSN] 0015-5314
  • [Journal-full-title] Fogorvosi szemle
  • [ISO-abbreviation] Fogorv Sz
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


83. Brouland JP, Gélébart P, Kovàcs T, Enouf J, Grossmann J, Papp B: The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis. Am J Pathol; 2005 Jul;167(1):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, the regulation of SERCA3 expression was analyzed in the context of the adenomatous polyposis coli/beta-catenin/T-cell factor 4 (TCF4) pathway and of specificity protein 1 (Sp1)-like factor-dependent transcription.
  • We report that SERCA3 expression increased along the crypts as cells differentiated in normal colonic mucosa and in hyperplastic polyps, was moderately and heterogeneously expressed in colonic adenomas with expression levels inversely correlated with the degree of dysplasia, was barely detectable in well and moderately differentiated adenocarcinomas, and was absent in poorly differentiated tumors.
  • These data link SERCA3 expression to the state of differentiation of colonic epithelial cells, and relate SERCA3 expression, already decreased in adenomas, to enhanced adenomatous polyposis coli/beta-catenin/TCF4-dependent signaling and deficient Sp1-like factor-dependent transcription.
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Blotting, Western. Cell Line, Tumor. Cell Transformation, Neoplastic. Colonic Polyps / enzymology. Cytoskeletal Proteins / genetics. DNA-Binding Proteins. Endoplasmic Reticulum / metabolism. Humans. Immunohistochemistry. Sarcoplasmic Reticulum Calcium-Transporting ATPases. TCF Transcription Factors. Trans-Activators / genetics. Transcription Factor 7-Like 2 Protein. Transcription Factors. Transfection. Transgenes. beta Catenin

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Jun 15;93(12):4395-405 [10361138.001]
  • [Cites] J Immunol. 1999 Jul 1;163(1):82-92 [10384103.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4266-70 [10485470.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5523-6 [7923189.001]
  • [Cites] Gene. 1999 Nov 29;240(2):261-7 [10580145.001]
  • [Cites] J Biol Chem. 1992 Jul 15;267(20):14483-9 [1385815.001]
  • [Cites] Am J Physiol. 1992 Sep;263(3 Pt 1):G371-9 [1415549.001]
  • [Cites] Cell Calcium. 1993 Jul;14(7):531-8 [8402836.001]
  • [Cites] J Clin Invest. 1993 Dec;92(6):2916-21 [7504695.001]
  • [Cites] Am J Med Sci. 1994 Mar;307(3):167-72 [8160706.001]
  • [Cites] J Mol Recognit. 1994 Sep;7(3):189-97 [7880543.001]
  • [Cites] Gastroenterology. 1995 Nov;109(5):1468-74 [7557127.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1995;26 Suppl 1:190-6 [8629105.001]
  • [Cites] Biosci Rep. 1995 Oct;15(5):299-306 [8825032.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28220-8 [8910439.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] J Biol Chem. 1997 Apr 18;272(16):10746-50 [9099725.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):22199-206 [9268365.001]
  • [Cites] Virchows Arch. 1997 Aug;431(2):111-7 [9293892.001]
  • [Cites] Cytokines Mol Ther. 1996 Jun;2(2):111-4 [9384695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Dec 8;241(1):142-50 [9405248.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1371-6 [10625687.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:195-9 [10667218.001]
  • [Cites] Science. 2000 Apr 14;288(5464):331-3 [10764645.001]
  • [Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]
  • [Cites] FEBS Lett. 2000 Jul 7;476(3):203-7 [10913614.001]
  • [Cites] Biol Pharm Bull. 2000 Aug;23(8):926-9 [10963297.001]
  • [Cites] Leuk Res. 2000 Oct;24(10):795-804 [10996197.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G806-14 [11005769.001]
  • [Cites] Lancet. 2000 Oct 14;356(9238):1300-6 [11073017.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12625-30 [11035797.001]
  • [Cites] Hepatogastroenterology. 2000 Sep-Oct;47(35):1291-7 [11100335.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):570-6 [11212251.001]
  • [Cites] Mol Cell Biol. 2001 Apr;21(7):2413-22 [11259590.001]
  • [Cites] Biol Chem. 2001 Feb;382(2):329-42 [11308031.001]
  • [Cites] J Cell Physiol. 2001 Aug;188(2):143-60 [11424081.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):25742-52 [11337508.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):249-56 [11812948.001]
  • [Cites] FEBS Lett. 2002 Mar 13;514(2-3):122-8 [11943137.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16673-81 [11872750.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26310-20 [11986315.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):307-15 [12123752.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):36471-8 [12119294.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):147-52 [12387883.001]
  • [Cites] Diabetes. 2002 Nov;51(11):3245-53 [12401716.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45579-91 [12207029.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):269-78 [12543089.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):279-305 [12543090.001]
  • [Cites] Cell Calcium. 2002 Nov-Dec;32(5-6):405-11 [12543099.001]
  • [Cites] J Mol Biol. 2003 Feb 21;326(3):665-77 [12581631.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):107-17 [12633551.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3220-8 [12515718.001]
  • [Cites] J Cell Sci. 2003 May 15;116(Pt 10):1861-2 [12692187.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):445-54 [12729578.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17785-91 [12624107.001]
  • [Cites] J Mol Endocrinol. 2003 Jun;30(3):399-409 [12790808.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):6023-31 [12955081.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):47877-89 [12975374.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] Nat Cell Biol. 2003 Dec;5(12):1041-3 [14647298.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 23;317(1):235-43 [15047174.001]
  • [Cites] Curr Mol Med. 2004 May;4(3):313-22 [15101688.001]
  • [Cites] Annu Rev Biochem. 2004;73:437-65 [15189149.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1223-36 [15336970.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Am J Surg Pathol. 1984 Sep;8(9):687-98 [6476197.001]
  • [Cites] Am J Med Sci. 1987 Nov;294(5):388-94 [2962490.001]
  • [Cites] Nihon Ketsueki Gakkai Zasshi. 1988 Jul;51(4):746-51 [3144112.001]
  • [Cites] Nucleic Acids Res. 1989 Jul 25;17(14):5447-59 [2548163.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2483-92 [1702327.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13982-94 [9593748.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9855-60 [9707565.001]
  • [Cites] Biochim Biophys Acta. 1999 Jan 18;1444(1):85-91 [9931450.001]
  • [Cites] Nutr Rev. 1999 Apr;57(4):124-6 [10228349.001]
  • [Cites] Biochem Cell Biol. 1998;76(5):779-85 [10353711.001]
  • (PMID = 15972967.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Trans-Activators; 0 / Transcription Factor 7-Like 2 Protein; 0 / Transcription Factors; 0 / beta Catenin; EC 3.6.3.8 / ATP2A3 protein, human; EC 3.6.3.8 / Calcium-Transporting ATPases; EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1603437
  •  go-up   go-down


84. Ionescu DN, Papachristou G, Schoen RE, Hedge M, Richards CS, Monzon FA: Attenuated familial adenomatous polyposis: a case report with mixed features and review of genotype-phenotype correlation. Arch Pathol Lab Med; 2005 Nov;129(11):1401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuated familial adenomatous polyposis: a case report with mixed features and review of genotype-phenotype correlation.
  • Familial adenomatous polyposis represents approximately 1% of all colorectal cancers and is caused by germline mutations in the adenomatous polyposis coli (APC) gene.
  • The relative location of the mutation may be associated with the number of polyps and partially predicts specific phenotypic expression.
  • We describe a patient with a mutation in codon 161 of the APC gene, which displays a phenotype most closely resembling the attenuated form of familial adenomatous polyposis, and review the literature, the implications of this mutation, and the importance of the molecular testing in the proper and more complete characterization of these patients.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli / pathology. Genes, APC. Germ-Line Mutation / genetics

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253019.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


85. Zhou PH, Yao LQ, Chen WF: [Endoscopic therapy of adenomatous polyps and early-stage carcinomas of the colon and rectum]. Zhonghua Wai Ke Za Zhi; 2008 Sep 15;46(18):1386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic therapy of adenomatous polyps and early-stage carcinomas of the colon and rectum].
  • OBJECTIVE: To assess the clinical efficacy of endoscopic treatment for colorectal adenomatous polyps and early-stage carcinomas.
  • METHODS: Between January 2006 and October 2007, 245 patients with colorectal adenomatous polyps and early-stage carcinomas with lifting sign(+) were treated by such endoscopic techniques as polypectomy, endoscopic mucosal resection (EMR), endoscopic piecemeal mucosal resection (EPMR) and endoscopic submucosal dissection (ESD).
  • CONCLUSIONS: Endoscopic resection appears to be an efficacious procedure to treat adenomatous polyp and early-stage carcinoma and provide pathological information about the whole lesion.
  • [MeSH-major] Adenomatous Polyps / surgery. Colorectal Neoplasms / surgery. Endoscopes, Gastrointestinal

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094508.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Sanduleanu S, Driessen A, Gomez-Garcia E, Hameeteman W, de Bruïne A, Masclee A: In vivo diagnosis and classification of colorectal neoplasia by chromoendoscopy-guided confocal laser endomicroscopy. Clin Gastroenterol Hepatol; 2010 Apr;8(4):371-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aims of this study were (1) to define and validate differential features of adenomatous and nonadenomatous colorectal polyps by chromoendoscopy-guided CLE (C-CLE) and (2) to assess predictive value of this technique for diagnosis of colorectal neoplasia.
  • RESULTS: In total, 116 colorectal polyps from 72 patients were examined.
  • Ex vivo histology showed 68 adenomas, 6 invasive carcinomas, 30 hyperplastic polyps, and 12 inflammatory polyps.
  • In contrast, C-CLE of nonadenomatous polyps revealed epithelial surface maturation, and minor abnormalities of crypt architecture and of vascular pattern, and maintained cell polarity.
  • Adenoma dysplasia score reliably discriminated high-grade dysplasia from low-grade dysplasia (accuracy, 96.7%).
  • CONCLUSIONS: C-CLE accurately discriminates adenomatous from nonadenomatous colorectal polyps and enables evaluation of degree of dysplasia during ongoing endoscopy.
  • [MeSH-major] Colonoscopy / methods. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Intestinal Polyps / diagnosis. Intestinal Polyps / pathology. Microscopy, Confocal / methods. Pathology / methods

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Clin Gastroenterol Hepatol. 2010 Apr;8(4):318-21 [20026427.001]
  • (PMID = 19683597.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Arditi C, Gonvers JJ, Burnand B, Minoli G, Oertli D, Lacaine F, Dubois RW, Vader JP, Schusselé Filliettaz S, Peytremann-Bridevaux I, Pittet V, Juillerat P, Froehlich F, EPAGE II Study Group: Appropriateness of colonoscopy in Europe (EPAGE II). Surveillance after polypectomy and after resection of colorectal cancer. Endoscopy; 2009 Mar;41(3):209-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Most CRCs arise from adenomatous polyps.
  • The characteristics of removed polyps, especially the distinction between low-risk adenomas (1 or 2, small [< 1 cm], tubular, no high-grade dysplasia) vs. high-risk adenomas (large [> or = 1 cm], multiple [> 3], high-grade dysplasia or villous features), have an impact on advanced adenoma recurrence.
  • [MeSH-major] Colonoscopy. Colorectal Neoplasms / surgery. Intestinal Polyps / surgery

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280532.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 115
  • [Investigator] Agréus L; Beglinger C; Bytzer P; Delvaux M; Eckardt V; Fairclough P; Lacaine F; Le Moine O; Lorenzo-Zúñiga V; Minoli G; Numans M; Oertli D; O'Malley J; Windsor A
  •  go-up   go-down


88. Rüschoff J, Heinmöller E, Hartmann A, Büttner R, Rau T: [Differential diagnostics of hereditary colorectal cancer syndromes. The role of pathology]. Pathologe; 2010 Oct;31(6):412-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Distinction between disease with and without polyposis, tumor histology and tumor spectrum in a given patient are all of diagnostic relevance.
  • Familial adenomatous polyposis (FAP) underlies approximately 1% of CRC characterized by rapidly forming (>100) adenomas.
  • In contrast to the other diseases MYH-associated polyposis (MAP) follows a recessive trait with polyp numbers usually between 15-30 adenomas and should be distinguished from attenuated forms of FAP with <100 polyps in the differential diagnosis.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Genetic Diseases, Inborn / diagnosis. Genetic Diseases, Inborn / pathology
  • [MeSH-minor] Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. DNA Mismatch Repair / genetics. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Microsatellite Instability. Mutation. Syndrome


89. Cappell MS: Reducing the incidence and mortality of colon cancer: mass screening and colonoscopic polypectomy. Gastroenterol Clin North Am; 2008 Mar;37(1):129-60, vii-viii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most colon cancers arise from conventional adenomatous polyps (conventional adenoma-to-carcinoma sequence), while some colon cancers appear to arise from the recently recognized serrated adenomatous polyp (serrated adenoma-to-carcinoma theory).
  • A minimal colonoscopic withdrawal time of 6 minutes is important to maximize polyp detection at colonoscopy.
  • Chromoendoscopy is an experimental technique used to highlight abnormal colonic areas to identify neoplastic tissue and to potentially determine the histology of colonic polyps at colonoscopy based on superficial pit anatomy.


90. Liang Z, Richards R: Virtual colonoscopy vs optical colonoscopy. Expert Opin Med Diagn; 2010 Mar 1;4(2):159-169
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Utilizing a strategy of virtual colonoscopy (VC) in asymptomatic patients over 50, with optical colonoscopy (OC) follow-up for removal of detected adenomatous polyps may result in lowering the colon cancer death rate.
  • However, the screening potential of VC has not yet been widely recognized.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20473367.001).
  • [ISSN] 1753-0067
  • [Journal-full-title] Expert opinion on medical diagnostics
  • [ISO-abbreviation] Expert Opin Med Diagn
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA082402; United States / NCI NIH HHS / CA / CA082402-07; United States / NCI NIH HHS / CA / CA120917-03; United States / NCI NIH HHS / CA / R21 CA120917; United States / NCI NIH HHS / CA / R33 CA120917
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] England
  •  go-up   go-down


91. Cappell MS: From colonic polyps to colon cancer: pathophysiology, clinical presentation, screening and colonoscopic therapy. Minerva Gastroenterol Dietol; 2007 Dec;53(4):351-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From colonic polyps to colon cancer: pathophysiology, clinical presentation, screening and colonoscopic therapy.
  • Yet, colon cancer is largely preventable through intensive, mass screening programs to remove premalignant colonic polyps.
  • Colon cancer mostly arises from adenomas, recognized as colonic polyps, but may occasionally arise from the sessile serrated adenoma.
  • Adenomatous polyposis coli (APC) gene mutation is the key molecular step in adenoma formation.
  • While colon cancer in an advanced and incurable stage often produces clinical findings, premalignant adenomatous polyps and early, highly curable, colon cancer are often asymptomatic.
  • All polyps identified at colonoscopy are removed by colonoscopic polypectomy.
  • Endoscopic mucosal resection is required for deeply penetrating noncancerous polyps.
  • Colonoscopy is repeated every ten years if the index colonoscopy revealed no lesions, but is repeated more frequently if adenomatous polyps were identified at this colonoscopy due to an increased risk of subsequent polyps or colon cancer.
  • [MeSH-major] Adenoma. Colonic Neoplasms. Colonic Polyps / complications. Colonoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043553.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 113
  •  go-up   go-down


92. de Ferro SM, Suspiro A, Fidalgo P, Lage P, Rodrigues P, Fragoso S, Vitoriano I, Baltazar C, Albuquerque C, Bettencourt A, Leitão CN: Aggressive phenotype of MYH-associated polyposis with jejunal cancer and intra-abdominal desmoid tumor: report of a case. Dis Colon Rectum; 2009 Apr;52(4):742-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MYH-associated polyposis is an inherited autosomal recessive disease, linked to biallelic germline MYH mutations, which predisposes to the development of multiple colorectal adenomas and cancer.
  • He presented at aged 30 years with more than 100 colonic polyps and 4 colonic adenocarcinomas.
  • Similar to patients with familial adenomatous polyposis, desmoid tumors also may be part of the clinical spectrum of MYH-associated polyposis and may prove to be a significant clinical problem in patients submitted to prophylactic colectomy.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Colorectal Neoplasms / genetics. Fibromatosis, Aggressive / genetics. Jejunal Neoplasms / genetics. Neoplasms, Multiple Primary / genetics. Peritoneal Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenoma / genetics. Adult. DNA Glycosylases / genetics. Duodenal Neoplasms / genetics. Genetic Predisposition to Disease. Germ-Line Mutation. Humans. Intestinal Neoplasms / genetics. Intestinal Obstruction / etiology. Liver Neoplasms / secondary. Male. Mesentery. Mutation. Phenotype. Syndrome


93. Moschos J, Tzilves D, Paikos D, Tagarakis G, Pilpilidis I, Antonopoulos Z, Kadis S, Katsos I, Tarpagos A: Large mesenteric gastrointestinal stromal tumor in a patient with familial adenomatous polyposis syndrome. Wien Klin Wochenschr; 2006 Jun;118(11-12):355-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mesenteric gastrointestinal stromal tumor in a patient with familial adenomatous polyposis syndrome.
  • Colonoscopy revealed many (>100) polyps (familial adenomatous polyposis syndrome).
  • We describe for the first time in medical literature the coexistence of familial adenomatous polyposis syndrome and GIST in a 30-year-old man.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli / diagnosis. Gastrointestinal Stromal Tumors / complications. Gastrointestinal Stromal Tumors / diagnosis. Mesentery / pathology

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):630-5 [14675690.001]
  • [Cites] Histol Histopathol. 2000 Oct;15(4):1293-301 [11005253.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Br J Surg. 1987 May;74(5):377-80 [3036290.001]
  • [Cites] Eur Radiol. 2002 Dec;12 Suppl 3:S82-5 [12522611.001]
  • [Cites] Turk J Gastroenterol. 2004 Sep;15(3):187-91 [15492920.001]
  • [Cites] Wien Klin Wochenschr. 2001 Jun 15;113(11-12):446-50 [11467091.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Surgery. 1989 May;105(5):668-70 [2539653.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):655-64 [12424067.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Gut. 1994 Mar;35(3):377-81 [8150351.001]
  • [Cites] Hum Pathol. 1978 May;9(3):269-83 [26633.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1149-53 [7577011.001]
  • [Cites] Eur J Surg Oncol. 1992 Dec;18(6):580-4 [1478290.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):318-9 [11231473.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1109-18 [10478672.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2005 Jan;34(1):11-4 [15796875.001]
  • (PMID = 16855925.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


94. Hartmann D, Bassler B, Schilling D, Adamek HE, Jakobs R, Pfeifer B, Eickhoff A, Zindel C, Riemann JF, Layer G: Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy. Radiology; 2006 Jan;238(1):143-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal polyps: detection with dark-lumen MR colonography versus conventional colonoscopy.
  • PURPOSE: To prospectively compare dark-lumen magnetic resonance (MR) colonography with conventional colonoscopy in the detection of colorectal polyps.
  • Results of MR colonography were analyzed on a per-polyp and per-patient basis.
  • In the other 49 patients (53%), conventional colonoscopy depicted 107 polyps (82 adenomas, 25 hyperplastic polyps) and seven carcinomas.
  • At per-polyp analysis, sensitivity of MR colonography in the detection of adenomatous polyps was 100% for polyps at least 10 mm in diameter and 84.2% for polyps 6-9 mm in diameter.
  • At per-patient analysis, the accuracy of MR colonography was 93.1% (sensitivity, 89%; specificity, 96%) if detection of adenomatous polyps of all sizes was considered.
  • CONCLUSION: Dark-lumen MR colonography is a promising modality with high accuracy for detecting colorectal polyps larger than 5 mm in diameter.
  • [MeSH-major] Colonic Polyps / diagnosis. Colonoscopy. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2005.
  • (PMID = 16304088.001).
  • [ISSN] 0033-8419
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; 15G12L5X8K / gadobenic acid; 6HG8UB2MUY / Meglumine
  •  go-up   go-down


95. Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, Potter JD: Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev; 2007 Dec;16(12):2697-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk.
  • Obesity has been shown to be associated with an increased risk of both colorectal cancer and adenomatous polyps.
  • We conducted a gastroenterology clinic-based, case-control study to evaluate the relationship between circulating leptin concentrations and colorectal adenoma risk; in addition, we evaluated the relationship between leptin receptor polymorphisms and adenoma risk.
  • Among men, those in the highest tertile of leptin concentrations had a 3.3-fold (95% confidence interval, 1.2-8.7) increased adenoma risk compared with those in the lowest tertile (P trend = 0.01).
  • There were no associations between leptin concentrations and adenoma risk in women.
  • There were no associations of leptin receptor genotypes or haplotypes and adenoma risk.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086776.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01CA74184; United States / NCI NIH HHS / CA / R03 CA110852; United States / NCI NIH HHS / CA / R25 CA094880; United States / NCI NIH HHS / CA / U01 CA074794; United States / NCI NIH HHS / CA / P01 CA074184; United States / NCI NIH HHS / CA / R25CA094880; United States / NCI NIH HHS / CA / R03CA11085
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leptin; 0 / Receptors, Leptin
  •  go-up   go-down


96. Celecoxib: new indication. Colorectal cancer: no preventive benefit. Prescrire Int; 2006 Feb;15(81):13-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) Familial adenomatous polyposis is a genetic disorder associated with multiple adenomatous colorectal polyps that invariably progress to colorectal cancer.
  • Gastroduodenal polyposis and extra-gastrointestinal desmoid tumours are other major sources of morbidity in these patients. (2) The current strategy used to prevent colorectal cancer in patients with APC gene mutations consists of yearly monitoring starting in adolescence, and prophylactic colectomy in early adulthood if polyposis occurs. (3) On the basis of pathophysiological, experimental and epidemiological evidence, some specialists have postulated that certain nonsteroidal antiinflammatory drugs (NSAIDs) might have a preventive effect on colorectal adenomas and cancer. (4) Aspirin and sulindac were tested for the prevention of polyps in patients with familial adenomatous polyposis, with uncertain results and weak evidence of effectiveness. (5) Celecoxib was tested in a comparative randomised double-blind trial lasting 6 months.
  • It involved 77 patients with familial polyposis and colorectal polyps, and 6 patients with only duodenal polyps.
  • On the basis of composite endoscopic criteria, a celecoxib dose of 800 mg/day (but not 200 mg/day) reduced the number and surface area of adenomatous colorectal polyps in patients with familial adenomatous polyposis.
  • It is not known whether celecoxib also reduced the risk of colorectal cancer.
  • A global qualitative analysis suggested that celecoxib was also effective in reducing duodenal polyps. (6) Nearly one-third of patients receiving celecoxib 800 mg/day in this trial developed rectal bleeding.
  • Another preventive trial was stopped when an excess of cardiovascular events was found in patients taking celecoxib. (7) The long-term risk-benefit balance of celecoxib 800 mg/day is not known nor whether efficacy persists after treatment discontinuation. (8) In practice, it is better not to use celecoxib to prevent colorectal cancer: its efficacy has not been demonstrated, even in familial polyposis, and it carries a major risk of bleeding and cardiovascular events.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16548099.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors; 0 / Pyrazoles; 0 / Sulfonamides
  •  go-up   go-down


97. Van Kerkhóve F, Coenegrachts K, Steyaert L, Van Den Berghe I, Casselman JW: Collision tumor in the ileum: a rare combination of an adenocarcinoma and small cell neuroendocrine tumor. JBR-BTR; 2006 Sep-Oct;89(5):258-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma, Villous / diagnosis. Adenomatous Polyps / diagnosis. Carcinoma, Small Cell / diagnosis. Ileal Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Tomography, X-Ray Computed. Ultrasonography


98. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM: Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A; 2008 Sep 9;105(36):13544-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
  • However, mTORC1's status in gastrointestinal tumors has not been characterized thoroughly.
  • We have found that the mTORC1 pathway is activated with increased expression of the mTOR protein in intestinal polyps of the Apc(Delta716) heterozygous mutant mouse, a model for human familial adenomatous polyposis.
  • An 8-week treatment with RAD001 (everolimus) suppressed the mTORC1 activity in these polyps and inhibited proliferation of the adenoma cells as well as tumor angiogenesis, which significantly reduced not only the number of polyps but also their size. beta-Catenin knockdown in the colon cancer cell lines reduced the mTOR level and thereby inhibited the mTORC1 signaling.
  • These results suggest that the Wnt signaling contributes to mTORC1 activation through the increased level of mTOR and that the activation plays important roles in the intestinal polyp formation and growth.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / metabolism. Intestinal Polyps / metabolism. Intestinal Polyps / prevention & control. Signal Transduction. Transcription Factors / metabolism
  • [MeSH-minor] Adenoma / blood supply. Adenoma / drug therapy. Adenoma / pathology. Animals. Cell Proliferation / drug effects. Everolimus. Female. Male. Mice. Mice, Transgenic. Multiprotein Complexes. Proteins. Sirolimus / analogs & derivatives. Sirolimus / pharmacology. Sirolimus / therapeutic use. Survival Rate. TOR Serine-Threonine Kinases. Wnt Proteins / metabolism


99. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R, Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev; 2006 Jun;15(6):1126-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammation-related gene polymorphisms and colorectal adenoma.
  • We hypothesized that a proinflammatory genotype would be positively associated with colorectal adenoma, a precursor of colorectal cancer.
  • We investigated the association of colorectal adenoma with 19 single nucleotide polymorphisms in a range of important proinflammatory (IL1B, IL6, IL8, TNF, and LTA) and anti-inflammatory (IL4, IL10, and IL13) cytokines and other inflammation-related genes (PTGS2 and PPARG) in a case-control study of risk factors for colorectal polyps in which all participants (ages 18-74 years) had undergone colonoscopy or sigmoidoscopy.
  • The study sample comprised 244 cases of colorectal adenoma and 231 polyp-free controls.
  • Compared with being homozygous for the common allele, heterozygosity at the IL1B -31 (C>T) locus was associated with an odds ratio (OR) for colorectal adenoma of 1.8 [95% confidence interval (95% CI), 1.2-2.9].
  • Homozygous carriers of the IL8 -251-A allele were at 2.7-fold increased risk of adenoma (95% CI, 1.5-4.9) compared with homozygosity for the common T allele, whereas carriage of at least one IL8 -251-A allele conferred a 1.5 increased odds of disease (95% CI, 1.0-2.4).
  • Among non-nonsteroidal anti-inflammatory drug users, there was a statistically significant association between the IL10 -819-T/T genotype and adenoma compared with the common IL10 -819-C/C genotype (OR, 3.9; 95% CI, 1.1-13.6), which was not evident among nonsteroidal anti-inflammatory drug users (OR, 0.7; 95% CI, 0.3-1.5; P(interaction) = 0.01).
  • These exploratory data provide evidence that polymorphic variation in genes that regulate inflammation could alter risk for colorectal adenoma.
  • [MeSH-major] Adenomatous Polyps / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. Cytokines / genetics. Cytokines / metabolism. Inflammation / genetics. Polymorphism, Single Nucleotide / genetics
  • [MeSH-minor] Adult. Aged. Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Case-Control Studies. Colonic Polyps / genetics. Colonic Polyps / pathology. Colonoscopy. Female. Genetic Variation. Humans. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775170.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor; 0 / Cytokines
  •  go-up   go-down


100. Gallagher MC, Phillips RK, Bulow S: Surveillance and management of upper gastrointestinal disease in Familial Adenomatous Polyposis. Fam Cancer; 2006;5(3):263-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surveillance and management of upper gastrointestinal disease in Familial Adenomatous Polyposis.
  • Almost all patients affected by Familial Adenomatous polyposis (FAP) will develop foregut as well as hindgut polyps, and following prophylactic colectomy duodenal cancer constitutes one of the leading causes of death in screened populations.
  • Management of the upper gastrointestinal cancer risk is one of the greatest challenges facing clinicians involved in the care of Polyposis families, and with improved survival following prophylactic colectomy, the burden of foregut disease (particularly duodenal adenomatosis) will increase.
  • [MeSH-major] Adenomatous Polyposis Coli / complications. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / therapy. Upper Gastrointestinal Tract / pathology